Misplaced Pages

Facioscapulohumeral muscular dystrophy
Other names	Landouzy–Dejerine muscular dystrophy, FSHMD, FSH
A diagram showing the muscles commonly affected by FSHD
Pronunciation	/ˌfeɪʃiːoʊˌskæpjəloʊˈhjuːmərəl/ fay-shee-oh-skap-yə-low-HEW-mər-əl alt. /feɪs-, fɑːʃ-, fɑːs-/
Specialty	Neurology, neuromuscular medicine
Symptoms	Facial weakness, scapular winging, foot drop
Complications	Chronic pain, dry eyes, and shoulder instability; less commonly retinal disease, scoliosis, and respiratory insufficiency
Usual onset	Ages 15 – 30 years
Duration	Lifelong
Types	Typically classified by genetic cause (FSHD1, FSHD2). Sometimes classified by disease manifestation (eg, infantile-onset)
Causes	Genetic (inherited or new mutation)
Risk factors	Male sex, extent of genetic mutation
Diagnostic method	Genetic testing
Differential diagnosis	Limb-girdle muscular dystrophy (especially calpainopathy), Pompe disease, mitochondrial myopathy, polymyositis
Management	Physical therapy, bracing, reconstructive surgery
Medication	Clinical trials ongoing
Prognosis	Progressive, unaffected life expectancy
Frequency	Up to 1/8,333

Facioscapulohumeral muscular dystrophy (FSHD) is a type of muscular dystrophy, a group of heritable diseases that cause degeneration of muscle and progressive weakness. Per the name, FSHD tends to sequentially weaken the muscles of the face, those that position the scapula, and those overlying the humerus bone of the upper arm. These areas can be spared, and muscles of other areas usually are affected, especially those of the chest, abdomen, spine, and shin. Almost any skeletal muscle can be affected in advanced disease. Abnormally positioned, termed 'winged', scapulas are common, as is the inability to lift the foot, known as foot drop. The two sides of the body are often affected unequally. Weakness typically manifests at ages 15–30 years. FSHD can also cause hearing loss and blood vessel abnormalities at the back of the eye.

FSHD is caused by a genetic mutation leading to deregulation of the DUX4 gene. Normally, DUX4 is expressed (i.e., turned on) only in select human tissues, most notably in the very young embryo. In the remaining tissues, it is repressed (i.e., turned off). In FSHD, this repression fails in muscle tissue, allowing sporadic expression of DUX4 throughout life. Deletion of DNA in the region surrounding DUX4 is the causative mutation in 95% of cases, termed "D4Z4 contraction" and defining FSHD type 1 (FSHD1). FSHD caused by other mutations is FSHD type 2 (FSHD2). For disease to develop, also required is a 4qA allele, which is a common variation in the DNA next to DUX4. The chances of a D4Z4 contraction with a 4qA allele being passed on to a child is 50% (autosomal dominant); in 30% of cases, the mutation arose spontaneously. Mutations of FSHD cause inadequate DUX4 repression by unpacking the DNA around DUX4, making it accessible to be copied into messenger RNA (mRNA). The 4qA allele stabilizes this DUX4 mRNA, allowing it to be used for production of DUX4 protein. DUX4 protein is a modulator of hundreds of other genes, many of which are involved in muscle function. How this genetic modulation causes muscle damage remains unclear.

Signs, symptoms, and diagnostic tests can suggest FSHD; genetic testing usually provides definitive diagnosis. FSHD can be presumptively diagnosed in an individual with signs/symptoms and an established family history. No intervention has proven effective for slowing progression of weakness. Screening allows for early detection and intervention for various disease complications. Symptoms can be addressed with physical therapy, bracing, and reconstructive surgery such as surgical fixation of the scapula to the thorax. FSHD affects up to 1 in 8,333 people, putting it in the three most common muscular dystrophies with myotonic dystrophy and Duchenne muscular dystrophy. Prognosis is variable. Many are not significantly limited in daily activity, whereas a wheel chair or scooter is required in 20% of cases. Life expectancy is not affected, although death can rarely be attributed to respiratory insufficiency due to FSHD.

FSHD was first distinguished as a disease in the 1870s and 1880s when French physicians Louis Théophile Joseph Landouzy and Joseph Jules Dejerine followed a family affected by it, thus the initial name Landouzy–Dejerine muscular dystrophy. Their work is predated by descriptions of probable individual FSHD cases. The significance of D4Z4 contraction on chromosome 4 was established in the 1990s. The DUX4 gene was discovered in 1999, found to be expressed and toxic in 2007, and in 2010 the genetic mechanism causing its expression was elucidated. In 2012, the gene most frequently mutated in FSHD2 was identified. In 2019, the first drug designed to counteract DUX4 expression entered clinical trials.

Signs and symptoms

Classically, weakness develops in the face, then the shoulder girdle, then the upper arm. These muscles can be spared and other muscles usually are affected. The order of muscle involvement can cause the appearance of weakness "descending" from the face to the legs. Distribution and degree of muscle weakness is extremely variable, even between identical twins. Musculoskeletal pain is very common, most often described in the neck, shoulders, lower back, and the back of the knee. Fatigue is also common. Muscle weakness usually becomes noticeable on one side of the body before the other, a hallmark of the disease. The right shoulder and arm muscles are more often affected than the left upper extremity muscles, independent of handedness. Otherwise, neither side of the body has been found to be at more risk. Classically, symptoms appear in those 15–30 years of age, although adult onset can also occur. Infantile-onset (also called early-onset), defined as onset of before age 10, occurs in 10% of affected individuals. FSHD1 with a very large D4Z4 deletion (EcoRI 10-11 kb) is more strongly associated with infantile onset and severe weakness. Absence or near absence of symptoms is not uncommon, approaching up to 30% of mutation-carrying individuals in select FSHD1 families. On average, FSHD2 presents 10 years later than FSHD1. Otherwise, FSHD1 and FSHD2 are indistinguishable on the basis of weakness. Disease progression is slow, and long static phases, in which no progression is apparent, is not uncommon. Less commonly, individual muscles rapidly deteriorate over several months. The symptom burden of FSHD is typically more severe than it is perceived to be by those without the disease.

Face

Weakness of the muscles of the face is the most distinguishing sign of FSHD. It is typically the earliest sign, although it is rarely the initial complaint. At least mild facial weakness can be found in 90% or more with FSHD. One of the most common deficits is inability to close the eyelids, which can result in sleeping with the eyelids open and dry eyes. The implicated muscle is the orbicularis oculi muscle. Another common deficit is inability to purse the lips, causing inability to pucker, whistle, or blow up a balloon. The implicated muscle is the orbicularis oris muscle. A third common deficit is inability raise the corners of the mouth, causing a "horizontal smile," which looks more like a grin. Responsible is the zygomaticus major muscle.

Weakness of facial muscles contributes to difficulty pronouncing words. Facial expressions can appear diminished, arrogant, grumpy, or fatigued. Muscles used for chewing and moving the eyes are not affected. Difficulty swallowing is not typical, although can occur in advanced cases, which is at least in part due to facial muscle weakness. FSHD is generally progressive, but it is not established whether facial weakness is progressive or stable throughout life.

Shoulder, chest, and arm

After the facial weakness, weakness usually develops in the muscles of the chest and those that span from scapula to thorax. Symptoms involving the shoulder, such as difficulty working with the arms overhead, are the initial complaint in 80% of cases. Predominantly, the serratus anterior and middle and lower trapezii muscles are affected; the upper trapezius is often spared. Trapezius weakness causes the scapulas to become downwardly rotated and protracted, resulting in winged scapulas, horizontal clavicles, and sloping shoulders; arm abduction is impaired. Serratus anterior weaknesss impairs arm flexion, and worsening of winging can be demonstrated when pushing against a wall. Muscles spanning from the scapula to the arm are generally spared, which include deltoid and the rotator cuff muscles. The deltoid can be affected later on, especially the upper portion.

Severe muscle wasting can make bones and spared shoulder muscles very visible, a characteristic example being the "poly-hill" sign elicited by arm elevation. The first "hill" or bump is the upper corner of scapula appearing to "herniate" up and over the rib cage. The second hill is the AC joint, seen between a wasted upper trapezius and wasted upper deltoid. The third hill is the lower deltoid, distinguishable between the wasted upper deltoid and wasted humeral muscles. Shoulder weakness and pain can in turn lead to shoulder instability, such as recurrent dislocation, subluxation, or downward translation of the humeral head.

Also affected is the chest, particularly the parts of the pectoralis major muscle that connect to the sternum and ribs. The part that connects to the clavicle is less often affected. This muscle wasting pattern can contribute to a prominent horizontal anterior axillary fold. Beyond this point the disease does not progress further in 30% of familial cases. After upper torso weakness, weakness can "descend" to the upper arms (biceps muscle and, particularly, the triceps muscle). The forearms are usually spared, resulting in an appearance some compare to the fictional character Popeye, although when the forearms are affected in advanced disease, the wrist extensors are more often affected.

Lower body and trunk

After the upper body, weakness can next appear in either the pelvis, or it "skips" the pelvis and involves the tibialis anterior (shin muscle), causing foot drop. One author considers the pelvic and thigh muscles to be the last group affected. Pelvic weakness can manifest as a Trendelenburg's sign. Weakness of the back of the thigh (hamstrings) is more common than weakness of the front of the thigh (quadriceps). In more severe cases, especially infantile FSHD, there can be anterior pelvic tilt, with associated hyperextension of the knees.

Weakness can also occur in the abdominal muscles and paraspinal muscles, which can manifest as a protuberant abdomen and lumbar hyperlordosis. Abdominal weakness can cause inability to do a sit-up or the inability to turn from one side to the other while lying on one's back. Of the rectus abdominis muscle, the lower portion is preferentially affected, manifesting as a positive Beevor's sign. In advanced cases, neck extensor weakness can cause the head to lean towards the chest, termed head drop.

Non-muscular

The most common non-musculoskeletal manifestation of FSHD is abnormalities in the small arteries (arterioles) in the retina. Tortuosity of the arterioles is seen in approximately 50% of those with FSHD. Less common arteriole abnormalities include telangiectasias and microaneurysms. These abnormalities of arterioles usually do not affect vision or health, although a severe form of it mimics Coat's disease, a condition found in about 1% of FSHD cases and more frequently associated with large 4q35 deletions. High-frequency sensorineural hearing loss can occur in those with large 4q35 deletions, but otherwise is no more common compared to the general population. Large 4q35 deletion can lead to various other rare manifestations.

Scoliosis can occur, thought to result from weakness of abdominal, hip extensor, and spinal muscles. Conversely, scoliosis can be viewed as a compensatory mechanism to weakness. Breathing can be affected, associated with kyphoscoliosis and wheelchair use; it is seen in one-third of wheelchair-using patients. However, ventilator support (nocturnal or diurnal) is needed in only 1% of cases. Although there are reports of increased risk of cardiac arrhythmias, general consensus is that the heart is not affected.

Genetics

The genetics of FSHD is complex. FSHD and the myotonic dystrophies have unique genetic mechanisms that differ substantially from the rest of genetic myopathies. The DUX4 gene is the focal point of FSHD genetics. Normally, full-length DUX4 protein (DUX4-fl) is expressed during early embryogenesis, in testicular tissue of adults, and in the thymus; in all other tissues it is repressed. In FSHD, within muscle tissue there is failure of DUX4 repression and continued production of DUX4-fl protein, which is toxic to muscles. The mechanism of failed DUX4 repression is hypomethylation of DUX4 and its surrounding DNA on the tip of chromosome 4 (4q35), allowing transcription of DUX4 into messenger RNA (mRNA). Several mutations can result in disease, upon which FSHD is sub-classified into FSHD type 1 (FSHD1) and FSHD type 2 (FSHD2). Disease can only result when a mutation is present in combination with select, commonly found variations of 4q35, termed haplotype polymorphisms, which are roughly dividable into the groups 4qA and 4qB. A 4qA haplotype polymorphism, often referred to as a 4qA allele, is necessary for disease, as it contains a polyadenylation sequence that allows DUX4 mRNA to resist degradation long enough to be translated into DUX4 protein.

DUX4 and the D4Z4 repeat array

DUX4 resides within the D4Z4 macrosatellite repeat array, which is a DNA sequence composed of a variable number of tandemly repeated large DNA segments (ie, repeats). The D4Z4 repeat array is located at the tip of the large arm of chromosome 4, abbreviated as '4q35'. Each D4Z4 repeat is 3.3 kilobase pairs (kb) long and is the site of epigenetic regulation, containing both heterochromatin and euchromatin structures. In FSHD, the heterochromatin structure is lost, becoming euchromatin, which consists of less methylation of DNA, and altered methylation of histones. Histone methylation patterns differ slightly between FSHD1 and FSHD2.

The subtelomeric region of chromosome 10q contains a tandem repeat structure highly homologous (99% identical) to 4q35, containing "D4Z4-like" repeats with protein-coding regions identical to DUX4 (D10Z10 repeats and DUX4L10, respectively). Because 10q usually lacks a polyadenylation sequence, it is usually not implicated in disease. However, chromosomal rearrangements can occur between 4q and 10q repeat arrays, and involvement in disease is possible if a 4q D4Z4 repeat and polyadenylation signal are transferred onto 10q, or if rearrangement causes FSHD1.

D4Z4 repeat array types are subclassified into 4qA and 4qB alleles, with only 4qA alleles causing disease. 4qA alleles are defined by a specific sequence of DNA immediately downstream to the D4Z4 repeat array: a 260 base pair region named pLAM, followed by a 6,200 base pair beta satellite region. 4qA and 4qB alleles, together, are able to be subdivided into at least 17 types, based on the DNA upstream from the D4Z4 repeat array, the presence/absence of restriction enzyme sites within D4Z4, the size of the last D4Z4 repeat element, and the DNA present downstream to the D4Z4 repeat array. For example, the most common 4qA allele, 4A161, has 161 nucleotides in the region upstream from the D4Z4 repeat array, and can in turn be subdivided into 4A161S and 4A161L (short and long), which are characterized by a flanking D4Z4 repeat units of 300 nucleotides and 1,900 nucleotides, respectively.

DUX4 consists of three exons. Exons 1 and 2 are in each repeat; only exon 1 encodes for DUX4 protein. Exon 3 is in the pLAM region telomeric to the last partial repeat, and it can vary in length depending on the type of 4qA allele. A polyadenylation signal is within exon 3. Because exon 3 and its containing polyadenylation signal are not contained within each D4Z4 repeat, only the last D4Z4 repeat of a D4Z4 repeat array can encode a stable mRNA transcript for the production of DUX4 protein. These transcripts can be spliced several different ways to form mature RNA. One of these transcripts encode only a portion of DUX4 protein, termed DUX4-s (DUX4-short). DUX4-s is found in low amounts in a variety of healthy tissues, including healthy muscle; its function is not entirely clear. The remaining transcript versions encode the full length of DUX4 protein (DUX4-fl), differing only in the noncoding regions. Only certain versions of these DUX4-fl encoding mature RNAs are implicated in FSHD. Beyond just the DUX4 region, multiple RNA transcripts are produced from the D4Z4 repeat array, both sense and antisense, some of which might be degraded in areas to produce si-like small RNAs. Some transcripts that originate centromeric to the D4Z4 repeat array at the non-deleted element (NDE), termed D4Z4 regulatory element transcripts (DBE-T), could play a role in DUX4 derepression. One proposed mechanism is that DBE-T leads to the recruitment of the trithorax-group protein Ash1L, an increase in H3K36me2-methylation, and ultimately de-repression of 4q35 genes.

FSHD1

FSHD involving deletion of D4Z4 repeats (termed 'D4Z4 contraction') on 4q is classified as FSHD1, which accounts for 95% of FSHD cases. Typically, chromosome 4 includes between 11 and 150 D4Z4 repeats. In FSHD1, there are 1–10 D4Z4 repeats. The number of repeats is roughly inversely related to disease severity. Namely, those with 8–10 repeats tend to have the mildest presentations, sometimes with no symptoms; those with 4–7 repeats have moderate disease that is highly variable; and those with 1–3 repeats are more likely to have severe, atypical, and early-onset disease. Deletion of the entire D4Z4 repeat array does not result in FSHD because then there are no complete copies of DUX4 to be expressed, although other birth defects result. One contracted D4Z4 repeat array with an adjoining 4qA allele is sufficient to cause disease, so inheritance is autosomal dominant. De novo (new) mutations are implicated in 10–30% of cases, up to 40% of which exhibit somatic mosaicism. In an individual with mosaic FSHD, the severity of disease is correlated to the proportion of their cells carrying the mutation.

It has been proposed that FSHD1 undergoes anticipation, a phenomenon primarily associated with trinucleotide repeat disorders in which disease manifestation worsens with each subsequent generation. As of 2019, more detailed studies are needed to definitively show whether or not anticipation occurs. If anticipation does occur in FSHD, the mechanism is different than that of trinucleotide repeat disorders, since D4Z4 repeats are much larger than trinucleotide repeats, an underabundance of repeats (rather than overabundance) causes disease, and the repeat array size in FSHD is stable across generations.

FSHD2

FSHD with a D4Z4 array repeat size of 11 or greater is classified as FSHD2, which constitutes 5% of FSHD cases. A 4qA allele is still required, and its adjacent D4Z4 repeat array is typically borderline shortened, with less than 30 repeats. A deactivating mutation of one of several DNA methylation genes is required for FSHD2, which contributes to hypomethylation of a borderline shortened D4Z4 repeat array, at which the genetic mechanism converges with FSHD1. At least 85% of FSHD2 cases involve mutations in the gene SMCHD1 (structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18. Specific mutations of SMCHD1 are also associated with Bosma arhinia and microphtalmia syndrome. Another cause of FSHD2 is mutation in DNMT3B (DNA methyltransferase 3B). Mutations in DNMT3B can also cause ICF syndrome. As of 2020, early evidence indicates that a third cause of FSHD2 is mutation of the LRIF1 gene, which encodes the protein ligand-dependent nuclear receptor-interacting factor 1 (LRIF1). LRIF1 is known to interact with the SMCHD1 protein. As of 2019, it is presumed that mutation of additional, unidentified genes can cause FSHD2.

For FSHD2 associated with SMCHD1 or DNMT3B mutation, only one allele needs to be abnormal. These FSHD2-causative genes are not located next to the required D4Z4 array/4qA allele within the genome, and are thus inherited independently, resulting in a biallelic digenic inheritance pattern. For example, one parent without FSHD can pass on an SMCHD1 mutation, and the other parent, also without FSHD, can pass on a borderline-shortened D4Z4/4qA allele, bearing a child with FSHD2. For FSHD2 associated with LRIF1 mutation, both LRIF1 alleles need to be mutated, which theoretically yields an even more complex inheritance pattern, termed trialleic digenic.

Two ends of a disease spectrum

FSHD1 and FSHD2 have been traditionally viewed as separate entities with distinct genetic causes (albeit, the downstream genetic mechanisms merge). Alternatively, the genetic causes of FSHD1 and FSHD2 can be viewed as risk factors, each contributing to an FSHD disease spectrum. Not rarely, an affected individual seems to have contributions from both. For example, in those with FSHD2, although they have do not have a 4qA allele with D4Z4 repeat number less than 11, they still have one less than 30 (shorter than the upper limit seen in the general population), suggesting that a large number of D4Z4 repeats can prevent the effects of an SMCHD1 mutation. Further studies may be needed to determine the upper limit of D4Z4 repeats in FSHD2.

In those with FSHD1 and FSHD2, that is, having 10 or fewer repeats with an adjacent 4qA allele and an SMCHD1 mutation, the disease manifests more severely, illustrating that the effects of each mutation are additive. A combined FSHD1/FSHD2 presentation is most common in those with 9–10 repeats. A possible explanation is that a sizable portion of the general population has 9–10 repeats with difficult to detect or no disease, yet with the additive effect of an SMCHD1 mutation, symptoms are severe enough for a diagnosis to be made. The 9–10 repeat size can be considered as an overlap zone between FSHD1 and FSDH2.

Pathophysiology

Molecular

As of 2020, there seems to be a consensus that aberrant expression of DUX4 in muscle is the cause of FSHD. DUX4 is expressed in extremely small amounts, detectable in 1 out of every 1000 immature muscle cells (myoblast), which appears to increase after myoblast maturation, in part because the cells fuse as they mature, and a single nucleus expressing DUX4 can provide DUX4 protein to neighboring nuclei from fused cells.

It remains an area of active research how DUX4 protein causes muscle damage. DUX4 protein is a transcription factor that regulates many other genes. Some of these genes are involved in apoptosis, such as p53, p21, MYC, and β-catenin, and indeed it seems that DUX4 protein makes muscle cells more prone to apoptosis. Other DUX4 protein-regulated genes are involved in oxidative stress, and indeed it seems that DUX4 expression lowers muscle cell tolerance of oxidative stress. Variation in the ability of individual muscles to handle oxidative stress could partially explain the muscle involvement patterns of FSHD. DUX4 protein downregulates many genes involved in muscle development, including MyoD, myogenin, desmin, and PAX7, and indeed DUX4 expression has shown to reduce muscle cell proliferation, differentiation, and fusion. DUX4 protein regulates a few genes that are involved in RNA quality control, and indeed DUX4 expression has been shown to cause accumulation of RNA with subsequent apoptosis. Estrogen seems to play a role in modifying DUX4 protein effects on muscle differentiation, which could explain why females are lesser affected than males, although it remains unproven.

The cellular hypoxia response has been reported in a single study to be the main driver of DUX4 protein-induced muscle cell death. The hypoxia-inducible factors (HIFs) are upregulated by DUX4 protein, possibly causing pathologic signaling leading to cell death.

Another study found that DUX4 expression in muscle cells led to the recruitment and alteration of fibrous/fat progenitor cells, which helps explain why muscles become replaced by fat and fibrous tissue.

A single study implicated RIPK3 in DUX4-mediated cell death.

Muscle histology

Unlike other muscular dystrophies, early muscle biopsies show only mild degrees of fibrosis, muscle fiber hypertrophy, and displacement of nuclei from myofiber peripheries (central nucleation). More often found is inflammation. There can be endomysial inflammation, primarily composed of CD8+ T-cells, although these cells do not seem to directly cause muscle fiber death. Endomysial blood vessels can be surrounded by inflammation, which is relatively unique to FSHD, and this inflammation contains CD4+ T-cells. Inflammation is succeeded by deposition of fat (fatty infiltration), then fibrosis. Individual muscle fibers can appear whorled, moth-eaten, and, especially, lobulated.

Muscle involvement pattern

Why certain muscles are preferentially affected in FSHD remains unknown. There are multiple trends of involvement seen in FSHD, possibly hinting at underlying pathophysiology. Individual muscles can weaken while adjacent muscles remain strong. The right shoulder and arm muscles are more often affected than the left upper extremity muscles, a pattern also seen in Poland syndrome and hereditary neuralgic amyotrophy; this could reflect a genetic, developmental/anatomic, or functional-related mechanism. The deltoid is often spared, which is not seen in any other condition that affects the muscles around the scapula.

Medical imaging (CT and MRI) have shown muscle involvement not readily apparent otherwise

• A single MRI study shows the teres major muscle to be commonly affected.
• The semimembranosus muscle, part of the hamstrings, is commonly affected, deemed by one author to be "the most frequently and severely affected muscle."
• Of the quadriceps muscles, the rectus femoris is preferentially affected
• Of the gastrocnemius, the medial section is preferentially affected;
• The iliopsoas, a hip flexor muscle, is very often spared.

Retinopathy

Tortuosity of the retinal arterioles, and less often microaneurysms and telangiectasia, are commonly found in FSHD. Abnormalities of the capillaries and venules are not observed. One theory for why the arterioles are selectively affected is that they contain smooth muscle. The degree of D4Z4 contraction correlates to the severity of tortuosity of arterioles. It has been hypothesized that retinopathy is due to DUX4-protein-induced modulation of the CXCR4–SDF1 axis, which has a role in endothelial tip cell morphology and vascular branching.

Diagnosis

FSHD can be presumptively diagnosed in many cases based on signs, symptoms, and/or non-genetic medical tests, especially if a first-degree relative has genetically confirmed FSHD. Genetic testing can provide definitive diagnosis. In the absence of an established family history of FSHD, diagnosis can be difficult due to the variability in how FSHD manifests.

Genetic testing

Genetic testing is the gold standard for FSHD diagnosis, as it is the most sensitive and specific test available. Commonly, FSHD1 is tested for first. A shortened D4Z4 array length (EcoRI length of 10 kb to 38 kb) with an adjacent 4qA allele supports FSHD1. If FSHD1 is not present, commonly FSHD2 is tested for next by assessing methylation at 4q35. Low methylation (less than 20%) in the context of a 4qA allele is sufficient for diagnosis. The specific mutation, usually one of various SMCHD1 mutations, can be identified with next-generation sequencing (NGS).

Assessing D4Z4 length

Measuring D4Z4 length is technically challenging due to the D4Z4 repeat array consisting of long, repetitive elements. For example, NGS is not useful for assessing D4Z4 length, because it breaks DNA into fragments before reading them, and it is unclear from which D4Z4 repeat each sequenced fragment came. In 2020, optical mapping became available for measuring D4Z4 array length, which is more precise and less labor-intensive than southern blot. Molecular combing is also available for assessing D4Z4 array length. These methods, which physical measure the size of the D4Z4 repeat array, require specially prepared high quality and high molecular weight genomic DNA (gDNA) from serum, increasing cost and reducing accessibility to testing.

Restriction fragment length polymorphism (RFLP) analysis was the first genetic test developed and is still used as of 2020, although it is being phased out by newer methods. It involves dicing the DNA with restriction enzymes and sorting the resulting restriction fragments by size using southern blot. The restriction enzymes EcoRI and BlnI are commonly used. EcoRI isolates the 4q and 10q repeat arrays, and BlnI dices the 10q sequence into small pieces, allowing 4q to be distinguished. The EcoRI restriction fragment is composed of three parts: 1) 5.7 kb proximal part, 2) the central, variable size D4Z4 repeat array, and 3) the distal part, usually 1.25 kb. The proximal portion has a sequence of DNA stainable by the probe p13E-11, which is commonly used to visualize the EcoRI fragment during southern blot. The name "p13E-11" reflects that it is a subclone of a DNA sequence designated as cosmid 13E during the human genome project. Considering that each D4Z4 repeat is 3.3 kb, and the EcoRI fragment contains about 5 kb of DNA that is not part of the D4Z4 repeat array, the number of D4Z4 units can be calculated.

D4Z4 repeats = (EcoRI length - 5) / 3.3

Sometimes 4q or 10q will have a combination of D4Z4 and D4Z4-like repeats due to DNA exchange between 4q and 10q, which can yield erroneous results, requiring more detailed workup. Sometimes D4Z4 repeat array deletions can include the p13E-11 binding site, warranting use of alternate probes.

Assessing methylation status

Methylation status of 4q35 is traditionally assessed after FSHD1 testing is negative. Methylation sensitive restriction enzyme (MSRE) digestion showing hypomethylation has long been considered diagnostic of FSHD2. Other methylation assays have been proposed or used in research settings, including methylated DNA immunoprecipitation and bisulfite sequencing, but are not routinely used in clinical practice. Bisulfite sequencing, if validated, would be valuable due to it being able to use lower quality DNA sources, such as those found in saliva.

Auxiliary testing

Other tests can support the diagnosis of FSHD, although they are all less sensitive and less specific than genetic testing. Nonetheless, they can rule out similar-appearing conditions.

• Creatine kinase (CK) blood level is often ordered when muscle damage is suspected. CK is an enzyme found in muscle, leaking into the blood when muscles become damaged. In FSHD, CK level is normal to mildly elevated, never exceeding five times the upper limit of normal.
• Electromyogram (EMG) measures the electrical activity in the muscle. EMG can show nonspecific signs of muscle damage or irritability.
• Nerve conduction velocity (NCV) measures the how fast signals travel along a nerve. The nerve signals are measured with surface electrodes (similar to those used for an electrocardiogram) or needle electrodes. FSHD does not affect nerve conduction velocity; abnormal nerve conduction would point towards a neuropathy rather than myopathy.
• Muscle biopsy is the surgical removal and examination of a small piece of muscle, usually from the arm or leg. Microscopy and a variety of biochemical tests are used for examination. Findings in FSHD are nonspecific, such as presence of white blood cells or variation in muscle fiber size. This test is rarely indicated.
• Magnetic resonance imaging (MRI) is sensitive for detecting muscle damage, even in mild cases. T1-weighted MRI imaging can visualize fatty infiltration of muscles, and T2-weighted MRI imaging can visualize muscle edema. MRI can help differentiate FSHD from other muscle diseases on the basis of the pattern of muscles involved, directing genetic testing.
• Ultrasound (US) can be used in the evaluation of muscles. US is effective at identifying fatty infiltration or scarring of muscles due to FSHD, manifesting as increased echogenicity (appearing brighter on ultrasound imaging). Advantages of US, compared to MRI or computed tomography, include low cost and no radiation exposure. However, US has poorer evaluation of deeper muscles, and ultrasonic findings tend to be more operator-dependent.
• Computed tomography (CT) imaging is not routinely used for muscle imaging due to significant radiation exposure and inferior characterization of soft tissues (ie, parts of the body other than bone). However, muscle that is incidentally imaged by CT can appear atrophied and lower density, because fat is less dense than muscle. CT has limited ability to detect the inflammatory changes of muscle that MRI can detect.

Differential diagnosis

Included in the differential diagnosis of FSHD are limb-girdle muscular dystrophy (especially calpainopathy), scapuloperoneal myopathy, mitochondrial myopathy, Pompe disease, and polymyositis. Calpainopathy and scapuloperoneal myopathy, like FSHD, present with scapular winging. Features that suggest FSHD are facial weakness, asymmetric weakness, and lack of benefit from immunosuppression medications. Features the suggest an alternative diagnosis are contractures, respiratory insufficiency, weakness of muscles controlling eye movement, and weakness of the tongue or throat.

Management

No pharmacologic treatment has proven to significantly slow progression of weakness or meaningfully improve strength.

Screening and monitoring of complications

The American Academy of Neurology (AAN) recommends several medical tests to detect complications of FSHD. A dilated eye exam to look for retinal abnormalities is recommended in those newly diagnosed with FSHD; for those with large D4Z4 deletions, an evaluation by a retinal specialist is recommended yearly. A hearing test is recommended for individuals with early-onset FSHD prior to starting school, or for any other FSHD-affected individual with symptoms of hearing loss. Pulmonary function testing (PFT) is recommended in those newly diagnosed to establish baseline pulmonary function, and recurrently for those with pulmonary insufficiency symptoms or risks. Routine screening for heart conditions, such as through an electrocardiogram (EKG) or echocardiogram (echo), is considered unnecessary in those without symptoms of heart disease.

Physical and occupational therapy

Aerobic exercise has been shown to reduce chronic fatigue and decelerate fatty infiltration of muscle in FSHD. Physical activity in general might slow disease progression in the legs. The AAN recommends that people with FSHD engage in low-intensity aerobic exercise to promote energy levels, muscle health, and bone health. Moderate-intensity strength training appears to do no harm, although it has not been shown to be beneficial. Physical therapy can address specific symptoms; there is no standardized protocol for FSHD. Anecdotal reports suggest that appropriately applied kinesiology tape can reduce pain. Occupational therapy can be used for training in activities of daily living (ADLs) and to help adapt to new assistive devices. Cognitive behavioral therapy (CBT) has been shown to reduce chronic fatigue in FSHD, and it also decelerates fatty infiltration of muscle when directed towards increasing daily activity.

Braces are often used to address muscle weakness. Scapular bracing can improve scapular positioning, which improves shoulder function, although it is often deemed as ineffective or impractical. Ankle-foot orthoses can improve walking, balance, and quality of life.

Pharmacologic management

No pharmaceuticals have definitively proven effective for altering the disease course. Although a few pharmaceuticals have shown improved muscle mass in limited respects, they did not improve quality of life, and the AAN recommends against their use for FSHD.

Reconstructive surgery

Scapular winging is amenable to surgical correction, namely operative scapular fixation. Scapular fixation is restriction and stabilization of the position of the scapula, putting it in closer apposition to the rib cage and reducing winging. Absolute restriction of scapular motion by fixation of the scapula to the ribs is most commonly reported. This procedure often involves inducing bony fusion, called arthrodesis, between the scapula and ribs. Names for this include scapulothoracic fusion, scapular fusion, and scapulodesis. This procedure increases arm active range of motion, improves arm function, decreases pain, and improves cosmetic appearance. Active range of motion of the arm increases most in the setting of severe scapular winging with an unaffected deltoid muscle; however, passive range of motion decreases. In other words, the patient gains the ability to slowly raise their arms to 90+ degrees, but they lose the ability to "throw" their arm up to a full 180 degrees. The AAN states that scapular fixation can be offered cautiously to select patients after balancing these benefits against the adverse consequences of surgery and prolonged immobilization.

Another form of operative scapular fixation is scapulopexy. "Scapulo-" refers to the scapula bone, and "-pexy" is derived from the Greek root "to bind." Some versions of scapulopexy accomplish essentially the same result as scapulothoracic fusion, but instead of inducing bony fusion, the scapula is secured to the ribs with only wire, tendon grafts, or other material. Some versions of scapulopexy do not completely restrict scapular motion, examples including tethering the scapula to the ribs, vertebrae, or other scapula. Scapulopexy is considered to be more conservative than scapulothoracic fusion, with reduced recovery time and less effect on breathing. However, they also seem more susceptible to long-term failure. Another form of scapular fixation, although not commonly done in FSHD, is tendon transfer, which involves surgically rearranging the attachments of muscles to bone. Examples include pectoralis major transfer and the Eden–Lange procedure.

Various other surgical reconstructions have been described. Upper eyelid gold implants have been used for those unable to close their eyes. Drooping lower lip has been addressed with plastic surgery. Ability to smile can theoretically be restored with a tendon transfer, with donors such as a portion of the temporalis muscle, although evidence is lacking in FSHD. Select cases of foot drop can be surgically corrected with tendon transfer, in which the tibialis posterior muscle is repurposed as a tibialis anterior muscle, a version of this being called the Bridle procedure. Severe scoliosis caused by FSHD can be corrected with spinal fusion; however, since scoliosis might be a compensatory change in response to muscle weakness, correction of spinal alignment can result in further impaired muscle function.

• Scapular winging management
• Kinesiology tape applied across the scapulas
• A cloth brace to hold the scapulas in retraction to reduce shoulder symptoms, such as collarbone pain
• Scapula-to-scapula scapulopexy, pre- and post-operation. The scapulas are tethered together into a retracted position with an Achilles tendon graft, which, in this case, rendered the rhomboid major muscles distinguishable.

Prognosis

Genetics partially predicts prognosis. Those with large D4Z4 repeat deletions (with a remaining D4Z4 repeat array size of 10–20 kbp, or 1–4 repeats) are more likely to have severe and early disease, as well as non-muscular symptoms. Those who have the genetic mutations of both FSHD1 and FSHD2 are more likely to have severe disease. It has also been observed that D4Z4 shortening is less and disease manifestation is milder when a prominent family history is present, as opposed to a new mutation. In some large families, 30% of those with the mutation had no noticeable symptoms, and 30% of those with symptoms did not progress beyond facial and shoulder weakness. Women tend to develop symptoms later in life and have less severe disease courses.

Remaining variations in disease course are attributed to unknown environmental factors. A single study found that disease course is not worsened by tobacco smoking or alcohol consumption, common risk factors for other diseases.

Pregnancy

Pregnancy outcomes are overall good in mothers with FSHD; there is no difference in rate of preterm labor, rate of miscarriage, and infant outcomes. However, weakness can increase the need for assisted delivery.

A single review found that weakness worsens, without recovery, in 12% of mothers with FSHD during pregnancy, although this might be due to weight gain or deconditioning.

Epidemiology

The prevalence of FSHD ranges from 1 in 8,333 to 1 in 15,000. The Netherlands reports a prevalence of 1 in 8,333, after accounting for the undiagnosed. The prevalence in the United States is commonly quoted as 1 in 15,000.

After genetic testing became possible in 1992, average prevalence was found to be around 1 in 20,000, a large increase compared to before 1992. However, 1 in 20,000 is likely an underestimation, since many with FSHD have mild symptoms and are never diagnosed, or they are siblings of affected individuals and never seek definitive diagnosis.

Race and ethnicity have not been shown to affect FSHD incidence or severity.

Although the inheritance of FSHD shows no predilection for biological sex, the disease manifests less often in women, and even when it manifests in women, they on average are less severely affected than affected males. Estrogen has been suspected to be a protective factor that accounts for this discrepancy. One study found that estrogen reduced DUX4 activity. However, another study found no association between disease severity and lifetime estrogen exposure in females. The same study found that disease progression was not different through periods of hormonal changes, such as menarche, pregnancy, and menopause.

History

The first description of a person with FSHD in medical literature appears in an autopsy report by Jean Cruveilhier in 1852. In 1868, Duchenne published his seminal work on Duchenne muscular dystrophy, and as part of its differential was a description of FSHD. First in 1874, then with a more commonly cited publication in 1884, and again with pictures in 1885, the French physicians Louis Landouzy and Joseph Dejerine published details of the disease, recognizing it as a distinct clinical entity, and thus FSHD is sometimes referred to as Landouzy Dejerine disease. In their paper of 1886, Landouzy and Dejerine drew attention to the familial nature of the disorder and mentioned that four generations were affected in the kindred that they had investigated. Formal definition of FSHD's clinical features did not occur until 1952 when a large Utah family with FSHD was studied. Beginning about 1980 an increasing interest in FSHD led to increased understanding of the great variability in the disease and a growing understanding of the genetic and pathophysiological complexities. By the late 1990s, researchers were finally beginning to understand the regions of chromosome 4 associated with FSHD.

Since the publication of the unifying theory in 2010, researchers continued to refine their understanding of DUX4. With increasing confidence in this work, researchers proposed the first a consensus view in 2014 of the pathophysiology of the disease and potential approaches to therapeutic intervention based on that model.

Alternate and historical names for FSHD include the following:

• facioscapulohumeral disease
• faciohumeroscapular
• Landouzy–Dejerine disease (or 'syndrome' or 'type of muscular dystrophy')
• Erb-Landouzy-Dejerine syndrome

Chronology of important FSHD-related genetic research

1861	Person with muscular dystrophy depicted by Duchenne. Based on the muscles involved, this person could have had FSHD.
1884	Landouzy and Dejerine describe a form of childhood progressive muscle atrophy with a characteristic involvement of facial muscles and distinct from pseudohypertrophic (Duchenne's MD) and spinal muscle atrophy in adults. Two brothers with FSHD followed by Landouzy and DejerinePhotograph of one brother at age 21. The right scapula is protracted, downwardly rotated, and laterally displaced.Drawing of another brother at age 17. Visible is lumbar hyperlordosis. The upper arm and pectoral muscles appear atrophied.
1886	Landouzy and Dejerine describe progressive muscular atrophy of the scapulo-humeral type.
1950	Tyler and Stephens study 1249 individuals from a single kindred with FSHD traced to a single ancestor and describe a typical Mendelian inheritance pattern with complete penetrance and highly variable expression. The term facioscapulohumeral dystrophy is introduced.
1982	Padberg provides the first linkage studies to determine the genetic locus for FSHD in his seminal thesis "Facioscapulohumeral disease."
1987	The complete sequence of the Dystrophin gene (Duchenne's MD) is determined.
1991	The genetic defect in FSHD is linked to a region (4q35) near the tip of the long arm of chromosome 4.
1992	FSHD, in both familial and de novo cases, is found to be linked to a recombination event that reduces the size of 4q EcoR1 fragment to < 28 kb (50–300 kb normally).
1993	4q EcoR1 fragments are found to contain tandem arrangement of multiple 3.3-kb units (D4Z4), and FSHD is associated with the presence of < 11 D4Z4 units. A study of seven families with FSHD reveals evidence of genetic heterogeneity in FSHD.
1994	The heterochromatic structure of 4q35 is recognized as a factor that may affect the expression of FSHD, possibly via position-effect variegation. DNA sequencing within D4Z4 units shows they contain an open reading frame corresponding to two homeobox domains, but investigators conclude that D4Z4 is unlikely to code for a functional transcript.
1995	The terms FSHD1A and FSHD1B are introduced to describe 4q-linked and non-4q-linked forms of the disease.
1996	FSHD Region Gene1 (FRG1) is discovered 100 kb proximal to D4Z4.
1998	Monozygotic twins with vastly different clinical expression of FSHD are described.
1999	Complete sequencing of 4q35 D4Z4 units reveals a promoter region located 149 bp 5' from the open reading frame for the two homeobox domains, indicating a gene that encodes a protein of 391 amino acid protein (later corrected to 424 aa), given the name DUX4.
2001	Investigators assessed the methylation state (heterochromatin is more highly methylated than euchromatin) of DNA in 4q35 D4Z4. An examination of SmaI, MluI, SacII, and EagI restriction fragments from multiple cell types, including skeletal muscle, revealed no evidence for hypomethylation in cells from FSHD1 patients relative to D4Z4 from unaffected control cells or relative to homologous D4Z4 sites on chromosome 10. However, in all instances, D4Z4 from sperm was hypomethylated relative to D4Z4 from somatic tissues.
2002	A polymorphic segment of 10 kb directly distal to D4Z4 is found to exist in two allelic forms, designated 4qA and 4qB. FSHD1 is associated solely with the 4qA allele. Three genes (FRG1, FRG2, ANT1) located in the region just centromeric to D4Z4 on chromosome 4 are found in isolated muscle cells from individuals with FSHD at levels 10 to 60 times greater than normal, showing a linkage between D4Z4 contractions and altered expression of 4q35 genes.
2003	A further examination of DNA methylation in different 4q35 D4Z4 restriction fragments (BsaAI and FseI) showed significant hypomethylation at both sites for individuals with FSHD1, non-FSHD-expressing gene carriers, and individuals with phenotypic FSHD relative to unaffected controls.
2004	Contraction of the D4Z4 region on the 4qB allele to < 38 kb does not cause FSHD.
2006	Transgenic mice overexpressing FRG1 are shown to develop severe myopathy.
2007	The DUX4 open reading frame is found to have been conserved in the genome of primates for over 100 million years, supporting the likelihood that it encodes a required protein. Researchers identify DUX4 mRNA in primary FSHD myoblasts and identify in D4Z4-transfected cells a DUX4 protein, the overexpression of which induces cell death. DUX4 mRNA and protein expression are reported to increase in myoblasts from FSHD patients, compared to unaffected controls. Stable DUX4 mRNA is transcribed only from the most distal D4Z4 unit, which uses an intron and a polyadenylation signal provided by the flanking pLAM region. DUX4 protein is identified as a transcription factor, and evidence suggests overexpression of DUX4 is linked to an increase in the target paired-like homeodomain transcription factor 1 (PITX1).
2009	The terms FSHD1 and FSHD2 are introduced to describe D4Z4-deletion-linked and non-D4Z4-deletion-linked genetic forms, respectively. In FSHD1, hypomethylation is restricted to the short 4q allele, whereas FSHD2 is characterized by hypomethylation of both 4q and both 10q alleles. Splicing and cleavage of the terminal (most telomeric) 4q D4Z4 DUX4 transcript in primary myoblasts and fibroblasts from FSHD patients is found to result in the generation of multiple RNAs, including small noncoding RNAs, antisense RNAs and capped mRNAs as new candidates for the pathophysiology of FSHD. Mechanism proposed of DBE-T (D4Z4 Regulatory Element transcript) leading to de-repression of 4q35 genes.
2010	A unifying genetic model of FSHD is established: D4Z4 contractions only cause FSHD when in the context of a 4qA allele due to stabilization of DUX4 RNA transcript, allowing DUX4 expression. Several organizations including The New York Times highlighted this research Francis Collins, who oversaw the first sequencing of the Human Genome with the National Institutes of Health stated: "If we were thinking of a collection of the genome's greatest hits, this would go on the list," Daniel Perez, co-founder of the FSHD Society, hailed the new findings saying: "This is a long-sought explanation of the exact biological workings of " The MDA stated that: "Now, the hunt is on for which proteins or genetic instructions (RNA) cause the problem for muscle tissue in FSHD." One of the report's co-authors, Silvère van der Maarel of the University of Leiden, stated that "It is amazing to realize that a long and frustrating journey of almost two decades now culminates in the identification of a single small DNA variant that differs between patients and people without the disease. We finally have a target that we can go after." DUX4 is found actively transcribed in skeletal muscle biopsies and primary myoblasts. FSHD-affected cells produce a full-length transcript, DUX4-fl, whereas alternative splicing in unaffected individuals results in the production of a shorter, 3'-truncated transcript (DUX4-s). The low overall expression of both transcripts in muscle is attributed to relatively high expression in a small number of nuclei (~ 1 in 1000). Higher levels of DUX4 expression in human testis (~100 fold higher than skeletal muscle) suggest a developmental role for DUX4 in human development. Higher levels of DUX4-s (vs DUX4-fl) are shown to correlate with a greater degree of DUX-4 H3K9me3-methylation.
2012	Some instances of FSHD2 are linked to mutations in the SMCHD1 gene on chromosome 18, and a genetic/mechanistic intersection of FSHD1 and FSHD2 is established. The prevalence of FSHD-like D4Z4 deletions on permissive alleles is significantly higher than the prevalence of FSHD in the general population, challenging the criteria for molecular diagnosis of FSHD. When expressed in primary myoblasts, DUX4-fl acted as a transcriptional activator, producing a > 3-fold change in the expression of 710 genes. A subsequent study using a larger number of samples identified DUX4-fl expression in myogenic cells and muscle tissue from unaffected relatives of FSHD patients, per se, is not sufficient to cause pathology, and that additional modifiers are determinants of disease progression.
2013	Mutations in SMCHD1 are shown to increase the severity of FSHD1. Transgenic mice carrying D4Z4 arrays from an FSHD1 allele (with 2.5 D4Z4 units), although lacking an obvious FSHD-like skeletal muscle phenotype, are found to recapitulate important genetic expression patterns and epigenetic features of FSHD.
2014	DUX4-fl and downstream target genes are expressed in skeletal muscle biopsies and biopsy-derived cells of fetuses with FSHD-like D4Z4 arrays, indicating that molecular markers of FSHD are already expressed during fetal development. Researchers "review how the contributions from many labs over many years led to an understanding of a fundamentally new mechanism of human disease" and articulate how the unifying genetic model and subsequent research represent a "pivot-point in FSHD research, transitioning the field from discovery-oriented studies to translational studies aimed at developing therapies based on a sound model of disease pathophysiology." They describe the consensus mechanism of pathophysiology for FSHD as an "inefficient repeat-mediated epigenetic repression of the D4Z4 macrosatellite repeat array on chromosome 4, resulting in the variegated expression of the DUX4 retrogene, encoding a double-homeobox transcription factor, in skeletal muscle."
2020	Voice of the Patient Report released documenting FSHD's impacts on daily life as conveyed by about 400 patients during an FDA externally led Patient-Focused Drug Development meeting, which was held on June 29, 2020.

Past pharmaceutical development

Early drug trials, before the pathogenesis involving DUX4 was discovered, were untargeted and largely unsuccessful. Compounds were trialed with goals of increasing muscle mass, decreasing inflammation, or addressing provisional theories of disease mechanism. The following drugs failed to show efficacy:

• Prednisone, a steroid, based on its antiinflammatory properties and therapeutic effect in Duchenne muscular dystrophy.
• Oral albuterol, a β2 agonist, on the basis of its anabolic properties. Although it improved muscle mass and certain measures of strength in those with FSHD, it did not improve global strength or function. Interestingly, β2 agonists were later shown to reduce DUX4 expression.
• Diltiazem, a calcium channel blocker, on the bases of anecdotal reports of benefit and the theory that calcium dysregulation played a part in muscle cell death.
• MYO-029 (stamulumab), an antibody that inhibits myostatin, was developed to promote muscle growth. Myostatin is a protein that inhibits the growth of muscle tissue.
• ACE-083, a TGF-β inhibitor, was developed to promote muscle growth.

Society and culture

Media

• In the Amazon Video series The Man in the High Castle, Obergruppenführer John Smith's son, Thomas, is diagnosed with Landouzy–Dejerine syndrome.
• In the biography Stuart: A Life Backwards, the protagonist was affected by muscular dystrophy, presumably FSHD.
• Good Bad Things, an independent film about an entrepreneur afflicted with FSHD and his journey of transformation, self-acceptance and discovery. The movie premiered at the 2024 Slamdance Film Festival
• The Lost Voice, a short film featuring Tristram Ingham who lives with FSHD. Ingham used Apple's Personal Voice feature to recreate his voice and use it to read a children's book titled The Lost Voice for International Day of Persons with Disabilities in 2023.

Patient and research organizations

• The FSHD Society (named "FSH Society" until 2019) was founded in 1991 on the East Coast by two individuals with FSHD, Daniel Perez and Stephen Jacobsen. The FSHD Society claims to have advocated for the standardization of the disease name facioscapulohumeral muscular dystrophy and its abbreviation FSHD. The FSHD Society claims to have raised funding for seed grants for FSHD research and co-wrote the MD-CARE Act of 2001, which provided federal funding for all muscular dystrophies. The FSHD Society has grown into the world's largest grassroots organization advocating for patient education and scientific and medical research for FSHD. One notable spokesperson for FSHD Society has been Max Adler, an actor on the TV series Glee.
• Friends of FSH Research is a research-oriented nonprofit organization founded in 2004 by Terry and Rick Colella from Kirkland, Washington, after their son was diagnosed with FSHD.
• The FSHD Global Research Foundation was founded in 2007 by Bill Moss in Australia, a former Macquarie Bank executive affected by FSHD. It is currently directed by Moss's daughter. It was named Australian charity of the year for 2017. It is the largest funder of FSHD medical research outside of the United States as of 2018.
• FSHD EUROPE was founded in 2010. Spanning multiple countries in Europe, it has launched the European Trial Network.

Notable cases

• Chip Wilson is a Canadian billionaire and founder of Lululemon. He has pledged 100 million Canadian dollars to research through the venture 'Solve FSHD'.
• Chris Carrino is the radio voice of the Brooklyn Nets. He founded the Chris Carrino Foundation for FSHD, oriented towards research funding.
• Madison Ferris is an American actress with FSHD who was the first wheelchair user to play a lead on Broadway.
• Morgan Hoffmann is an American professional golfer. He started the Morgan Hoffmann Foundation, oriented towards research funding.
• Arnold Gold (1925–2024) was a pediatric neurologist, founder of the Arnold P. Gold Foundation, and creator of white coat ceremonies. Gold focused on patient-centered care and humanism.

Research directions

Pharmaceutical development

After achieving consensus on FSHD pathophysiology in 2014, researchers proposed four approaches for therapeutic intervention:

1. enhance the epigenetic repression of the D4Z4
2. target the DUX4 mRNA, including altering splicing or polyadenylation;
3. block the activity of the DUX4 protein
4. inhibit the DUX4-induced process, or processes, that leads to pathology.

Small molecule drugs

Most drugs used in medicine are "small molecule drugs," as opposed to biologic medical products that include proteins, vaccines, and nucleic acids. Small molecule drugs can typically be taken by ingestion, rather than injection.

• Losmapimod, a selective inhibitor of p38α/β mitogen-activated protein kinases, was identified by Fulcrum Therapeutics as a potent suppressor of DUX4 in vitro. Results of a phase IIb clinical trial, revealed in June 2021, showed statistically significant slowing of muscle function deterioration. Further trials are pending.
• Casein kinase 1 (CK1) inhibition has been identified by Facio Therapies, a Dutch pharmaceutical company, to repress DUX4 expression and is in preclinical development. Facio Therapies claims that CK1 inhibition leaves myotube fusion intact, unlike BET inhibitors, p38 MAPK inhibitors, and β2 agonists.

Gene therapy

Gene therapy is the administration of nucleotides to treat disease. Multiple types of gene therapy are in the preclinical stage of development for the treatment of FSHD.

• Antisense therapy utilizes antisense oligonucleotides that bind to DUX4 messenger RNA, inducing its degradation and preventing DUX4 protein production. Phosphorodiamidate morpholinos, an oligonucleotide modified to increase its stability, have been shown to selectively reduce DUX4 and its effects; however, these antisense nucleotides have poor ability to penetrate muscle.
• MicroRNAs (miRNAs) directed against DUX4, delivered by viral vectors, have shown to reduce DUX4, protect against muscle pathology, and prevent loss of grip strength in mouse FSHD models. Arrowhead pharmaceuticals is developing an RNA interference therapeutic against DUX4, named ARO-DUX4, and intends to file for regulatory clearance in third quarter of 2021 to begin clinical trials.
• Genome editing, the permanent alteration of genetic code, is being researched. One study tried to use CRISPR-Cas9 to knockout the polyadenylation signal in lab dish models, but was unable to show therapeutic results.

Potential drug targets

• Inhibition of the hyaluronic acid (HA) pathway is a potential therapy. One study found that many DUX4-induced molecular pathologies are mediated by HA signaling, and inhibition of HA biosynthesis with 4-methylumbelliferone prevented these molecular pathologies.
• P300 inhibition has shown to inhibit the deleterious effects of DUX4
• BET inhibitors have been shown to reduce DUX4 expression.
• Antioxidants could potentially reduce the effects of FSHD. One study found that vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation increased endurance and strength of the quadriceps, but had no significant benefit on walking performance. Further study is warranted.

Outcome measures

Ways of measuring the disease are important for studying disease progression and assessing the efficacy of drugs in clinical trials.

• Reachable workspace uses the Kinect motion sensing system to compare range of reach before and after a therapeutic clinical trial.
• Quality of life can be measured with questionnaires, such as the FSHD Health Index.
• How the disease affects daily activities can measured with questionnaires, such as the FSHD‐Rasch‐built overall disability scale (FSHD-RODS) or FSHD composite outcome measure (FSHD-COM).
• Electrical impedance myography is being studied as a way to measure muscle damage.
• Muscle MRI is useful for assessment of all the muscles in the body. Muscles can be scored based on the degree of fat infiltration.

References

1. The sources listed below differ on pronunciation of the 'u' in 'scapulo'. A 'long u' sound in an unstressed nonfinal syllable is often reduced to a schwa and varies by speaker.
   • "Facioscapulohumeral". Merriam-Webster.com Dictionary. Merriam-Webster.
   • "Facioscapulohumeral". Medical Dictionary, Farlex and Partners, 2009.
2. ^ Wagner KR (December 2019). "Facioscapulohumeral Muscular Dystrophies". CONTINUUM: Lifelong Learning in Neurology. 25 (6): 1662–1681. doi:10.1212/CON.0000000000000801. PMID 31794465. S2CID 208531681.
3. Stedman T (1987). Webster's New World/Stedman's Concise Medical Dictionary (1 ed.). Baltimore: Williams & Wilkins. p. 230. ISBN 0-13-948142-7.
4. ^ Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van Engelen BG (June 2016). "What's in a name? The clinical features of facioscapulohumeral muscular dystrophy". Practical Neurology. 16 (3): 201–207. doi:10.1136/practneurol-2015-001353. PMID 26862222. S2CID 4481678.
5. ^ Kumar V, Abbas A, Aster J, eds. (2018). Robbins Basic Pathology (Tenth ed.). Philadelphia, Pennsylvania: Elsevier. p. 844. ISBN 978-0-323-35317-5.
6. De Iaco A, Planet E, Coluccio A, Verp S, Duc J, Trono D (June 2017). "DUX-family transcription factors regulate zygotic genome activation in placental mammals". Nature Genetics. 49 (6): 941–945. doi:10.1038/ng.3858. PMC 5446900. PMID 28459456.
7. ^ Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG (28 October 2010). "Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene". PLOS Genetics. 6 (10): e1001181. doi:10.1371/journal.pgen.1001181. PMC 2965761. PMID 21060811.
8. ^ Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camaño P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, Tawil R, Frants RR, van der Maarel SM (19 August 2010). "A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy" (PDF). Science. 329 (5999): 1650–3. Bibcode:2010Sci...329.1650L. doi:10.1126/science.1189044. hdl:1887/117104. PMC 4677822. PMID 20724583. Archived from the original (PDF) on 2014-06-05.
9. ^ Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. (November 2007). "Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy". Am. J. Hum. Genet. 81 (5): 884–94. doi:10.1086/521986. PMC 2265642. PMID 17924332.
10. ^ Mul K (1 December 2022). "Facioscapulohumeral Muscular Dystrophy". Continuum (Minneapolis, Minn.). 28 (6): 1735–1751. doi:10.1212/CON.0000000000001155. PMID 36537978. S2CID 254883066.
11. ^ Eren İ, Birsel O, Öztop Çakmak Ö, Aslanger A, Gürsoy Özdemir Y, Eraslan S, Kayserili H, Oflazer P, Demirhan M (May 2020). "A novel shoulder disability staging system for scapulothoracic arthrodesis in patients with facioscapulohumeral dystrophy". Orthopaedics & Traumatology: Surgery & Research. 106 (4): 701–707. doi:10.1016/j.otsr.2020.03.002. PMID 32430271.
12. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones K, Krishnamurthi R, Feigin V (2014). "Prevalence of muscular dystrophies: a systematic literature review". Neuroepidemiology. 43 (3–4): 259–68. doi:10.1159/000369343. hdl:10292/13206. PMID 25532075. S2CID 2426923.
13. Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, Jette N (January 2016). "A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies". The Canadian Journal of Neurological Sciences. 43 (1): 163–77. doi:10.1017/cjn.2015.311. PMID 26786644. S2CID 24936950.
14. ^ Tawil R, Van Der Maarel SM (July 2006). "Facioscapulohumeral muscular dystrophy" (PDF). Muscle & Nerve. 34 (1): 1–15. doi:10.1002/mus.20522. PMID 16508966. S2CID 43304086.
15. ^ Statland JM, Tawil R (December 2016). "Facioscapulohumeral Muscular Dystrophy". Continuum (Minneapolis, Minn.). 22 (6, Muscle and Neuromuscular Junction Disorders): 1916–1931. doi:10.1212/CON.0000000000000399. PMC 5898965. PMID 27922500.
16. ^ Cruveilhiers J (1852–1853). "Mémoire sur la paralysie musculaire atrophique". Bulletins de l'Académie de Médecine. 18: 490–502, 546–583.
17. ^ Rogers MT (2004). "Facioscapulohumeral muscular dystrophy: historical background and literature review". In Upadhyaya M, Cooper DN (eds.). FSHD facioscapulohumeral muscular dystrophy: clinical medicine and molecular cell biology. BIOS Scientific Publishers. ISBN 1-85996-244-0.
18. ^ Landouzy L, Dejerine J (1885). Landouzy L, Lépine R (eds.). "De la myopathie atrophique progressive (myopathie sans neuropathie débutant d'ordinaire dans l'enfance par la face)". Revue de Médecine (in French). 5. Felix Alcan: 253–366. Retrieved 19 May 2020.
19. ^ Cohen J, DeSimone A, Lek M, Lek A (October 2020). "Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy". Trends in Molecular Medicine. 27 (2): 123–137. doi:10.1016/j.molmed.2020.09.008. PMC 8048701. PMID 33092966.
20. ^ Tupler R, Barbierato L, et al. (Sep 1998). "Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression". Journal of Medical Genetics. 35 (9): 778–783. doi:10.1136/jmg.35.9.778. PMC 1051435. PMID 9733041.
21. Tawil R, Storvick D, Feasby TE, Weiffenbach B, Griggs RC (February 1993). "Extreme variability of expression in monozygotic twins with FSH muscular dystrophy". Neurology. 43 (2): 345–8. doi:10.1212/wnl.43.2.345. PMID 8094896. S2CID 44422140.
22. Pandya S, Eichinger K. "Physical Therapy for Facioscapulohumeral Muscular Dystrophy" (PDF). FSHD Society. Archived from the original (PDF) on 14 April 2020. Retrieved 14 April 2020.
23. ^ Padberg GW (1982-10-13). Facioscapulohumeral disease (Thesis). Leiden University.
24. ^ Padberg GW (2004). "Facioscapulohumeral muscular dystrophy: a clinician's experience". In Upadhyaya M, Cooper DN (eds.). FSHD Facioscapulohumeral Muscular Dystrophy: Clinical Medicine and Molecular Cell Biology. BIOS Scientific Publishers. ISBN 1-85996-244-0.
25. ^ Rijken NH, van der Kooi EL, Hendriks JC, van Asseldonk RJ, Padberg GW, Geurts AC, van Engelen BG (December 2014). "Skeletal muscle imaging in facioscapulohumeral muscular dystrophy, pattern and asymmetry of individual muscle involvement". Neuromuscular Disorders. 24 (12): 1087–96. doi:10.1016/j.nmd.2014.05.012. PMID 25176503. S2CID 101093.
26. Bergsma A, Cup EH, Janssen MM, Geurts AC, de Groot IJ (February 2017). "Upper limb function and activity in people with facioscapulohumeral muscular dystrophy: a web-based survey". Disability and Rehabilitation. 39 (3): 236–243. doi:10.3109/09638288.2016.1140834. PMID 26942834. S2CID 4237308.
27. ^ Tawil R, van der Maarel SM, Tapscott SJ (10 June 2014). "Facioscapulohumeral dystrophy: the path to consensus on pathophysiology". Skeletal Muscle. 4 (1): 12. doi:10.1186/2044-5040-4-12. PMC 4060068. PMID 24940479.
28. Jia FF, Drew AP, Nicholson GA, Corbett A, Kumar KR (2 October 2021). "Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings". Neuromuscular Disorders. 31 (11): 1101–1112. doi:10.1016/j.nmd.2021.09.010. PMID 34711481. S2CID 238246093.
29. ^ Upadhyaya M, Cooper D, eds. (March 2004). FSHD Facioscapulohumeral Muscular Dystrophy: Clinical Medicine and Molecular Cell Biology. BIOS Scientific Publishers. ISBN 0-203-48367-7.
30. ^ The FDA held an externally-led Patient-Focused Drug Development meeting with about 400 FSHD patients on June 29, 2020, resulting in a seminal document called the "Voice of the Patient Report." The report captures the impact of FSHD on the daily lives of those with the disease as conveyed by the patients themselves. While FSHD is often perceived to be "mild," the report shows that over 80% of patients report being "moderately" or "severely" limited in daily activities.
    • Society F. "FSHD Society releases Voice of the Patient Report on FSH muscular dystrophy". PRWeb. Retrieved 2024-01-31.
31. ^ Society F. "Facioscapulohumeral muscular dystrophy community speaks to the FDA". PRWeb. Retrieved 2024-01-31.
32. ^ Voice of the Patient Forum - Patient-Focused Drug Development Meeting, 29 June 2020, retrieved 2024-01-31
33. ^ Overman D (2020-11-13). "People Living with FSHD Tell Their Stories in New Report". Rehab Management. Retrieved 2024-01-31.
34. ^ Mul K, Berggren KN, Sills MY, McCalley A, van Engelen B, Johnson NE, Statland JM (26 February 2019). "Effects of weakness of orofacial muscles on swallowing and communication in FSHD". Neurology. 92 (9): e957–e963. doi:10.1212/WNL.0000000000007013. PMC 6404471. PMID 30804066.
35. Wohlgemuth M, de Swart BJ, Kalf JG, Joosten FB, Van der Vliet AM, Padberg GW (27 June 2006). "Dysphagia in facioscapulohumeral muscular dystrophy". Neurology. 66 (12): 1926–8. doi:10.1212/01.wnl.0000219760.76441.f8. PMID 16801662. S2CID 7695047.
36. ^ "A giant of FSHD research shares his "regrets"". FSHD Society. Way Back Machine. 30 September 2020. Archived from the original on 24 October 2020. Retrieved 11 March 2021. Another striking aspect of FSHD is that muscles weakness seems to vary so much from patient to patient. Nonetheless, "there is a highly characteristic pattern of muscle weakness, otherwise we would never have been able to recognize FSHD as a specific disease," Padberg said. "Strong deltoid muscle does not occur in any other condition that involves weakness of scapular stabilizers. No other muscle disease with shoulder girdle involvement has this pattern." Unfortunately, "an explanation is beyond our grasp as we don't know how muscle are laid down" during the early stages of human gestation.
37. ^ Tasca G, Monforte M, Iannaccone E, Laschena F, Ottaviani P, Leoncini E, Boccia S, Galluzzi G, Pelliccioni M, Masciullo M, Frusciante R, Mercuri E, Ricci E (2014). "Upper girdle imaging in facioscapulohumeral muscular dystrophy". PLOS ONE. 9 (6): e100292. Bibcode:2014PLoSO...9j0292T. doi:10.1371/journal.pone.0100292. PMC 4059711. PMID 24932477.
38. ^ Gerevini S, Scarlato M, Maggi L, Cava M, Caliendo G, Pasanisi B, Falini A, Previtali SC, Morandi L (March 2016). "Muscle MRI findings in facioscapulohumeral muscular dystrophy". European Radiology. 26 (3): 693–705. doi:10.1007/s00330-015-3890-1. PMID 26115655. S2CID 24650482.
39. Faux-Nightingale A, Kulshrestha R, Emery N, Pandyan A, Willis T, Philp F (September 2021). "Upper limb rehabilitation in fascioscapularhumeral dystrophy (FSHD): a patients' perspective". Archives of Rehabilitation Research and Clinical Translation. 3 (4): 100157. doi:10.1016/j.arrct.2021.100157. ISSN 2590-1095. PMC 8683863. PMID 34977539.
40. Pandya S, King WM, Tawil R (1 January 2008). "Facioscapulohumeral Dystrophy". Physical Therapy. 88 (1): 105–113. doi:10.2522/ptj.20070104. PMID 17986494.
41. Liew WK, van der Maarel SM, Tawil R (2015). "Facioscapulohumeral Dystrophy". Neuromuscular Disorders of Infancy, Childhood, and Adolescence. pp. 620–630. doi:10.1016/B978-0-12-417044-5.00032-9. ISBN 978-0-12-417044-5.
42. ^ Goselink R, Schreur V, van Kernebeek CR, Padberg GW, van der Maarel SM, van Engelen B, Erasmus CE, Theelen T (2019). "Ophthalmological findings in facioscapulohumeral dystrophy". Brain Communications. 1 (1): fcz023. doi:10.1093/braincomms/fcz023. PMC 7425335. PMID 32954265.
43. Padberg GW, Brouwer OF, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, Frants RR (1995). "On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy". Muscle & Nerve. 18 (S13): S73–S80. doi:10.1002/mus.880181314. hdl:2066/20764. S2CID 27523889.
44. Lindner M, Holz FG, Charbel Issa P (2016-04-27). "Spontaneous resolution of retinal vascular abnormalities and macular oedema in facioscapulohumeral muscular dystrophy". Clinical & Experimental Ophthalmology. 44 (7): 627–628. doi:10.1111/ceo.12735. ISSN 1442-6404. PMID 26933772. S2CID 204996841.
45. Trevisan CP, Pastorello E, Tomelleri G, Vercelli L, Bruno C, Scapolan S, Siciliano G, Comacchio F (December 2008). "Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions". European Journal of Neurology. 15 (12): 1353–8. doi:10.1111/j.1468-1331.2008.02314.x. PMID 19049553. S2CID 26276887.
46. ^ Eren İ, Abay B, Günerbüyük C, Çakmak ÖÖ, Şar C, Demirhan M (February 2020). "Spinal fusion in facioscapulohumeral dystrophy for hyperlordosis: A case report". Medicine. 99 (8): e18787. doi:10.1097/MD.0000000000018787. PMC 7034682. PMID 32080072.
47. Huml RA, Perez DP (2015). "FSHD: The Most Common Type of Muscular Dystrophy?". Muscular Dystrophy. pp. 9–19. doi:10.1007/978-3-319-17362-7_3. ISBN 978-3-319-17361-0.
48. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW (2004). "Ventilatory support in facioscapulohumeral muscular dystrophy". Neurology. 63 (1): 176–8. CiteSeerX 10.1.1.543.2968. doi:10.1212/01.wnl.0000133126.86377.e8. PMID 15249635. S2CID 31335126.
49. Dowling JJ, Weihl CC, Spencer MJ (November 2021). "Molecular and cellular basis of genetically inherited skeletal muscle disorders". Nature Reviews. Molecular Cell Biology. 22 (11): 713–732. doi:10.1038/s41580-021-00389-z. PMC 9686310. PMID 34257452. S2CID 235822532.
50. ^ Jagannathan S (1 May 2022). "The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1868 (5): 166367. doi:10.1016/j.bbadis.2022.166367. PMC 9173005. PMID 35158020.
51. ^ Lemmers RJ, O'Shea S, Padberg GW, Lunt PW, van der Maarel SM (May 2012). "Best practice guidelines on genetic diagnostics of Facioscapulohumeral muscular dystrophy: Workshop 9th June 2010, LUMC, Leiden, The Netherlands". Neuromuscular Disorders. 22 (5): 463–470. doi:10.1016/j.nmd.2011.09.004. PMID 22177830. S2CID 39898514.
52. The name "D4Z4" is derived from an obsolete nomenclature system used for DNA segments of unknown significance during the human genome project: D for DNA, 4 for chromosome 4, Z indicates it is a repetitive sequence, and 4 is a serial number assigned based on the order of submission.
    • White J, McAlpine P, Antonarakis S, Cann H, Eppig J, Frazer K, Frezal J, Lancet D, Nahmias J, Pearson P, Peters J, Scott A, Scott H, Spurr N, Talbot C, Povey S (October 1997). "NOMENCLATURE". Genomics. 45 (2): 468–471. doi:10.1006/geno.1997.4979. PMID 9344684.
    • Fasman KH, Letovsky SI, Cottingham RW, Kingsbury DT (1 January 1996). "Improvements to the GDB Human Genome Data Base". Nucleic Acids Research. 24 (1): 57–63. doi:10.1093/nar/24.1.57. PMC 145602. PMID 8594601.
53. ^ Impossible Things: Through the looking glass with FSH Dystrophy Researchers, Margaret Wahl, MDA, Quest magazine, Vol 14, No 2, March–April 2007
54. Dixit M, Ansseau E, Tassin A, et al. (November 2007). "DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1". Proc. Natl. Acad. Sci. U.S.A. 104 (46): 18157–62. Bibcode:2007PNAS..10418157D. doi:10.1073/pnas.0708659104. PMC 2084313. PMID 17984056.
55. ^ Šikrová D, Testa AM, Willemsen I, van den Heuvel A, Tapscott SJ, Daxinger L, Balog J, van der Maarel SM (28 June 2023). "SMCHD1 and LRIF1 converge at the FSHD-associated D4Z4 repeat and LRIF1 promoter yet display different modes of action". Communications Biology. 6 (1): 677. doi:10.1038/s42003-023-05053-0. PMC 10307901. PMID 37380887.
56. Coppée F, Mattéotti C, Anssaeu E, Sauvage S, Leclercq I, Leroy A, Marcowycz A, Gerbaux C, Figlewicz D, Ding H, Belayew B (2004). "The DUX gene family and FSHD". In Upadhyaya M, Cooper DN (eds.). FSHD facioscapulohumeral muscular dystrophy: clinical medicine and molecular cell biology. BIOS Scientific Publishers. ISBN 1-85996-244-0.
57. Rossi M, Ricci E, Colantoni L, et al. (2007). "The Facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure". BMC Med. Genet. 8: 8. doi:10.1186/1471-2350-8-8. PMC 1821008. PMID 17335567.
58. Lemmers R, van der Vliet PJ, Blatnik A, Balog J, Zidar J, Henderson D, Goselink R, Tapscott SJ, Voermans NC, Tawil R, Padberg G, van Engelen BG, van der Maarel SM (12 January 2021). "Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene". Journal of Medical Genetics. 59 (2): jmedgenet-2020-107041. doi:10.1136/jmedgenet-2020-107041. PMC 8273184. PMID 33436523. S2CID 231589589.
59. ^ Lemmers RJ, van der Vliet PJ, Balog J, Goeman JJ, Arindrarto W, Krom YD, Straasheijm KR, Debipersad RD, Özel G, Sowden J, Snider L, Mul K, Sacconi S, van Engelen B, Tapscott SJ, Tawil R, van der Maarel SM (January 2018). "Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2". European Journal of Human Genetics. 26 (1): 94–106. doi:10.1038/s41431-017-0015-0. PMC 5838976. PMID 29162933.
60. Sidlauskaite E, Le Gall L, Mariot V, Dumonceaux J (28 July 2020). "DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation". Journal of Personalized Medicine. 10 (3): 73. doi:10.3390/jpm10030073. PMC 7564753. PMID 32731450.
61. Himeda CL, Jones PL (31 August 2019). "The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy". Annual Review of Genomics and Human Genetics. 20: 265–291. doi:10.1146/annurev-genom-083118-014933. PMID 31018108. S2CID 131775712.
62. ^ Cabianca DS, Casa C, Bodega B, et al. (May 11, 2012). "A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy". Cell. 149 (4): 819–831. doi:10.1016/j.cell.2012.03.035. PMC 3350859. PMID 22541069.
63. ^ Sacconi S, Briand-Suleau A, Gros M, Baudoin C, Lemmers R, Rondeau S, Lagha N, Nigumann P, Cambieri C, Puma A, Chapon F, Stojkovic T, Vial C, Bouhour F, Cao M, Pegoraro E, Petiot P, Behin A, Marc B, Eymard B, Echaniz-Laguna A, Laforet P, Salviati L, Jeanpierre M, Cristofari G, van der Maarel SM (7 May 2019). "FSHD1 and FSHD2 form a disease continuum". Neurology. 92 (19): e2273–e2285. doi:10.1212/WNL.0000000000007456. PMC 6537132. PMID 30979860.
64. Tupler R, Berardinelli A, Barbierato L, Frants R, Hewitt JE, Lanzi G, Maraschio P, Tiepolo L (May 1996). "Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy". Journal of Medical Genetics. 33 (5): 366–70. doi:10.1136/jmg.33.5.366. PMC 1050603. PMID 8733044.
65. Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, King W, Weiffenbach B, Figlewicz D (June 1996). "Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group". Annals of Neurology. 39 (6): 744–8. doi:10.1002/ana.410390610. PMID 8651646. S2CID 84518968.
66. Zernov N, Skoblov M (13 March 2019). "Genotype-phenotype correlations in FSHD". BMC Medical Genomics. 12 (Suppl 2): 43. doi:10.1186/s12920-019-0488-5. PMC 6416831. PMID 30871534.
67. Sacconi S, Salviati L, Desnuelle C (April 2015). "Facioscapulohumeral muscular dystrophy". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1852 (4): 607–14. doi:10.1016/j.bbadis.2014.05.021. PMID 24882751.
68. ^ Lemmers RJ, Tawil R, Petek LM, et al. (Dec 2012). "Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2". Nature Genetics. 44 (12): 1370–1374. doi:10.1038/ng.2454. PMC 3671095. PMID 23143600.
69. van den Boogaard ML, Lemmers R, Balog J, Wohlgemuth M, Auranen M, Mitsuhashi S, van der Vliet PJ, Straasheijm KR, van den Akker R, Kriek M, Laurense-Bik M, Raz V, van Ostaijen-Ten Dam MM, Hansson K, van der Kooi EL, Kiuru-Enari S, Udd B, van Tol M, Nishino I, Tawil R, Tapscott SJ, van Engelen B, van der Maarel SM (5 May 2016). "Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy". American Journal of Human Genetics. 98 (5): 1020–1029. doi:10.1016/j.ajhg.2016.03.013. PMC 4863565. PMID 27153398.
70. ^ Johnson NE, Statland JM (7 May 2019). "FSHD1 or FSHD2: That is the question: The answer: It's all just FSHD". Neurology. 92 (19): 881–882. doi:10.1212/WNL.0000000000007446. PMID 30979855. S2CID 111390628.
71. ^ Hamanaka K, Šikrová D, Mitsuhashi S, Masuda H, Sekiguchi Y, Sugiyama A, Shibuya K, Lemmers RJ, Goossens R, Ogawa M, Nagao K, Obuse C, Noguchi S, Hayashi YK, Kuwabara S, Balog J, Nishino I, van der Maarel SM (28 May 2020). "Homozygous nonsense variant in associated with facioscapulohumeral muscular dystrophy". Neurology. 94 (23): e2441–e2447. doi:10.1212/WNL.0000000000009617. PMC 7455367. PMID 32467133. S2CID 218982743.
72. Schäffer AA (October 2013). "Digenic inheritance in medical genetics". Journal of Medical Genetics. 50 (10): 641–52. doi:10.1136/jmedgenet-2013-101713. PMC 3778050. PMID 23785127.
73. ^ Caputo V, Megalizzi D, Fabrizio C, Termine A, Colantoni L, Caltagirone C, Giardina E, Cascella R, Strafella C (29 August 2022). "Update on the Molecular Aspects and Methods Underlying the Complex Architecture of FSHD". Cells. 11 (17): 2687. doi:10.3390/cells11172687. PMC 9454908. PMID 36078093.
74. ^ Sacconi S, Lemmers RJ, Balog J, et al. (Oct 3, 2013). "The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1". The American Journal of Human Genetics. 93 (4): 744–751. doi:10.1016/j.ajhg.2013.08.004. PMC 3791262. PMID 24075187.
75. ^ Lim K, Nguyen Q, Yokota T (22 January 2020). "DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy". International Journal of Molecular Sciences. 21 (3): 729. doi:10.3390/ijms21030729. PMC 7037115. PMID 31979100.
76. ^ Bosnakovski D, Shams AS, Yuan C, da Silva MT, Ener ET, Baumann CW, Lindsay AJ, Verma M, Asakura A, Lowe DA, Kyba M (6 April 2020). "Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice". Journal of Clinical Investigation. 130 (5): 2465–2477. doi:10.1172/JCI133303. PMC 7190912. PMID 32250341.
77. Mocciaro E, Runfola V, Ghezzi P, Pannese M, Gabellini D (26 November 2021). "DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy". Cells. 10 (12): 3322. doi:10.3390/cells10123322. PMC 8699294. PMID 34943834.
78. ^ Schätzl T, Kaiser L, Deigner HP (12 March 2021). "Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update". Orphanet Journal of Rare Diseases. 16 (1): 129. doi:10.1186/s13023-021-01760-1. PMC 7953708. PMID 33712050. S2CID 232202360.
79. Lek A, Zhang Y, Woodman KG, Huang S, DeSimone AM, Cohen J, Ho V, Conner J, Mead L, Kodani A, Pakula A, Sanjana N, King OD, Jones PL, Wagner KR, Lek M, Kunkel LM (25 March 2020). "Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy". Science Translational Medicine. 12 (536): eaay0271. doi:10.1126/scitranslmed.aay0271. PMC 7304480. PMID 32213627.
80. Mariot V, Joubert R, Le Gall L, Sidlauskaite E, Hourde C, Duddy W, Voit T, Bencze M, Dumonceaux J (22 October 2021). "RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophy". Journal of Cachexia, Sarcopenia and Muscle. 12 (6): 2079–2090. doi:10.1002/jcsm.12813. PMC 8718031. PMID 34687171. S2CID 239471655.
81. Wang LH, Friedman SD, Shaw D, Snider L, Wong CJ, Budech CB, Poliachik SL, Gove NE, Lewis LM, Campbell AE, Lemmers R, Maarel SM, Tapscott SJ, Tawil RN (2019-02-01). "MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD". Human Molecular Genetics. 28 (3): 476–486. doi:10.1093/hmg/ddy364. PMC 6337697. PMID 30312408.
82. Gherardi R, Amato AA, Lidov HG, Girolami UD (Nov 2018). "Pathology of Skeletal Muscle". In Gray F, Duyckaerts C, Girolami Ud (eds.). Escourolle and Poirier's manual of basic neuropathology (Sixth ed.). New York, NY: Oxford University Press. doi:10.1093/med/9780190675011.001.0001. ISBN 978-0-19-067501-1.
83. van der Maarel SM, Miller DG, Tawil R, Filippova GN, Tapscott SJ (October 2012). "Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation". Current Opinion in Neurology. 25 (5): 614–20. doi:10.1097/WCO.0b013e328357f22d. PMC 3653067. PMID 22892954.
84. ^ Mair D, Huegens-Penzel M, Kress W, Roth C, Ferbert A (2017). "Leg Muscle Involvement in Facioscapulohumeral Muscular Dystrophy: Comparison between Facioscapulohumeral Muscular Dystrophy Types 1 and 2". European Neurology. 77 (1–2): 32–39. doi:10.1159/000452763. PMID 27855411. S2CID 25005883.
85. ^ Olsen DB, Gideon P, Jeppesen TD, Vissing J (November 2006). "Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI". Journal of Neurology. 253 (11): 1437–41. doi:10.1007/s00415-006-0230-z. PMID 16773269. S2CID 19421344.
86. Sacconi S, Salviati L, Bourget I, Figarella D, Péréon Y, Lemmers R, van der Maarel S, Desnuelle C (2006-10-24). "Diagnostic challenges in facioscapulohumeral muscular dystrophy". Neurology. 67 (8): 1464–6. doi:10.1212/01.wnl.0000240071.62540.6f. hdl:11577/1565214. PMID 17060574. S2CID 25693278.
87. Strafella C, Caputo V, Galota RM, Campoli G, Bax C, Colantoni L, Minozzi G, Orsini C, Politano L, Tasca G, Novelli G, Ricci E, Giardina E, Cascella R (1 December 2019). "The variability of SMCHD1 gene in FSHD patients: evidence of new mutations". Human Molecular Genetics. 28 (23): 3912–3920. doi:10.1093/hmg/ddz239. PMC 6969370. PMID 31600781.
88. Zampatti S, Colantoni L, Strafella C, Galota RM, Caputo V, Campoli G, Pagliaroli G, Carboni S, Mela J, Peconi C, Gambardella S, Cascella R, Giardina E (May 2019). "Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era". Neurogenetics. 20 (2): 57–64. doi:10.1007/s10048-019-00575-4. PMID 30911870. S2CID 85495566.
89. Kinoshita J (11 March 2020). "Genetic testing for FSHD—a new frontier". FSHD Society. Archived from the original on 8 April 2020. Retrieved 8 April 2020.
90. Vasale J, Boyar F, Jocson M, Sulcova V, Chan P, Liaquat K, Hoffman C, Meservey M, Chang I, Tsao D, Hensley K, Liu Y, Owen R, Braastad C, Sun W, Walrafen P, Komatsu J, Wang JC, Bensimon A, Anguiano A, Jaremko M, Wang Z, Batish S, Strom C, Higgins J (December 2015). "Molecular combing compared to Southern blot for measuring D4Z4 contractions in FSHD". Neuromuscular Disorders. 25 (12): 945–51. doi:10.1016/j.nmd.2015.08.008. PMID 26420234. S2CID 6871094.
91. ^ Gould T, Jones TI, Jones PL (13 August 2021). "Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects". Diagnostics (Basel, Switzerland). 11 (8): 1469. doi:10.3390/diagnostics11081469. PMC 8393475. PMID 34441403.
92. ^ van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. (Dec 1993). "FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit". Human Molecular Genetics. 2 (12): 2037–2042. doi:10.1093/hmg/2.12.2037. PMID 8111371.
93. ^ Wijmenga C, Hewitt JE, Sandkuijl LA, et al. (Sep 1992). "Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy". Nature Genetics. 2 (1): 26–30. doi:10.1038/ng0992-26. PMID 1363881. S2CID 21940164.
94. Frants RR, Sandkuijl LA, van der Maarel SM, Padberg GW (2004). "Mapping of the FSHD gene and the discovery of the pathognomonic deletion". In Upadhyaya M, Cooper DN (eds.). FSHD Facioscapulohumeral Muscular Dystrophy: Clinical Medicine and Molecular Cell Biology. BIOS Scientific Publishers. ISBN 1-85996-244-0.
95. Lemmers RJ, Vliet PJ, Granado DS, Stoep N, Buermans H, Schendel R, Schimmel J, Visser M, Coster R, Jeanpierre M, Laforet P, Upadhyaya M, Engelen B, Sacconi S, Tawil R, Voermans NC, Rogers M, van der Maarel SM (24 September 2021). "High resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect". Human Molecular Genetics. 31 (5): 748–760. doi:10.1093/hmg/ddab250. PMC 8895739. PMID 34559225.
96. Gaillard MC, Roche S, Dion C, Tasmadjian A, Bouget G, Salort-Campana E, Vovan C, Chaix C, Broucqsault N, Morere J, Puppo F, Bartoli M, Levy N, Bernard R, Attarian S, Nguyen K, Magdinier F (19 August 2014). "Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers" (PDF). Neurology. 83 (8): 733–42. doi:10.1212/WNL.0000000000000708. PMID 25031281. S2CID 10002229.
97. FSHD Fact Sheet Archived 2006-03-06 at the Wayback Machine, MDA, 11/1/2001
98. ^ Wattjes MP, Kley RA, Fischer D (October 2010). "Neuromuscular imaging in inherited muscle diseases". European Radiology. 20 (10): 2447–60. doi:10.1007/s00330-010-1799-2. PMC 2940021. PMID 20422195.
99. ^ Preston MK, Tawil R, Wang LH, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Mirzaa G, Amemiya A (1993). "Facioscapulohumeral Muscular Dystrophy". PMID 20301616. {{cite journal}}: Cite journal requires |journal= (help)
100. ^ Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M (28 July 2015). "Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine". Neurology. 85 (4): 357–64. doi:10.1212/WNL.0000000000001783. PMC 4520817. PMID 26215877.
101. ^ Tawil R, van der Maarel S, Padberg GW, van Engelen BG (July 2010). "171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy". Neuromuscular Disorders. 20 (7): 471–5. doi:10.1016/j.nmd.2010.04.007. PMID 20554202. S2CID 18448196.
102. ^ Voet N, Bleijenberg G, Hendriks J, de Groot I, Padberg G, van Engelen B, Geurts A (18 November 2014). "Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD: an RCT". Neurology. 83 (21): 1914–22. doi:10.1212/WNL.0000000000001008. PMID 25339206. S2CID 25382403.
103. ^ Janssen B, Voet N, Geurts A, van Engelen B, Heerschap A (3 May 2016). "Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients". Neurology. 86 (18): 1700–7. doi:10.1212/WNL.0000000000002640. PMID 27037227. S2CID 11617226.
104. Voet NB, van der Kooi EL, van Engelen BG, Geurts AC (6 December 2019). "Strength training and aerobic exercise training for muscle disease". The Cochrane Database of Systematic Reviews. 2019 (12): CD003907. doi:10.1002/14651858.CD003907.pub5. ISSN 1469-493X. PMC 6953420. PMID 31808555.
105. ^ Tawil R, Mah JK, Baker S, Wagner KR, Ryan MM, Sydney Workshop P (July 2016). "Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015". Neuromuscular Disorders. 26 (7): 462–71. doi:10.1016/j.nmd.2016.03.007. PMID 27185458.
106. "Information for Patients and Families - The Richard Fields Center for FSH Dystrophy (FSHD) & Neuromuscular Research - University of Rochester Medical Center". www.urmc.rochester.edu. Archived from the original on 14 November 2019. Retrieved 14 April 2020.
107. Aprile I, Bordieri C, Gilardi A, Lainieri Milazzo M, Russo G, De Santis F, Frusciante R, Iannaccone E, Erra C, Ricci E, Padua L (April 2013). "Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses". European Journal of Physical and Rehabilitation Medicine. 49 (2): 169–78. PMID 23138679.
108. ^ Orrell RW, Copeland S, Rose MR (20 January 2010). "Scapular fixation in muscular dystrophy". Cochrane Database of Systematic Reviews. 2010 (1): CD003278. doi:10.1002/14651858.CD003278.pub2. PMC 7144827. PMID 20091543.
109. Demirhan M, Uysal O, Atalar AC, Kilicoglu O, Serdaroglu P (31 March 2009). "Scapulothoracic Arthrodesis in Facioscapulohumeral Dystrophy with Multifilament Cable". Clinical Orthopaedics and Related Research. 467 (8): 2090–2097. doi:10.1007/s11999-009-0815-9. PMC 2706357. PMID 19333668.
110. DeFranco MJ, Nho S, Romeo AA (April 2010). "Scapulothoracic Fusion". Journal of the American Academy of Orthopaedic Surgeons. 18 (4): 236–42. doi:10.5435/00124635-201004000-00006. PMID 20357232. S2CID 27456684.
111. Heller KD, Prescher A, Forst J, Stadtmüller A, Forst R (1996). "Anatomo-experimental study for lace fixation of winged scapula in muscular dystrophy". Surgical and Radiologic Anatomy. 18 (2): 75–9. doi:10.1007/BF01795222. PMID 8782311. S2CID 20162712.
112. Abrams JS, Bell RH, Tokish JM (2018). ADVANCED RECONSTRUCTION OF SHOULDER. AMER ACAD OF ORTHOPAEDIC. ISBN 978-1-9751-2347-5.
113. ^ Upadhyaya M, Cooper DN (2004). "Introduction and overview of FSHD". In Upadhyaya M, Cooper DN (eds.). FSHD Facioscapulohumeral Muscular Dystrophy: Clinical Medicine and Molecular Cell Biology. BIOS Scientific Publishers. ISBN 1-85996-244-0.
114. Sansone V, Boynton J, Palenski C (June 1997). "Use of gold weights to correct lagophthalmos in neuromuscular disease". Neurology. 48 (6): 1500–3. doi:10.1212/wnl.48.6.1500. hdl:2434/210652. PMID 9191754. S2CID 16251273.
115. Matsumoto M, Onoda S, Uehara H, Miura Y, Katayama Y, Kimata Y (September 2016). "Correction of the Lower Lip With a Cartilage Graft and Lip Resection in Patients With Facioscapulohumeral Muscular Dystrophy". The Journal of Craniofacial Surgery. 27 (6): 1427–9. doi:10.1097/SCS.0000000000002720. PMID 27300465. S2CID 16343571.
116. Rasing NB, van de Geest-Buit WA, Chan OY, Mul K, Lanser A, van Engelen BG, Erasmus CE, Fischer AH, Ingels KJ, Post B, Siemann I, Groothuis JT, Voermans NC (21 March 2024). "Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases". Journal of Neuromuscular Diseases. 11 (3): 535–565. doi:10.3233/JND-230213. PMC 11091602. PMID 38517799.
117. Krishnamurthy S, Ibrahim M (January 2019). "Tendon Transfers in Foot Drop". Indian Journal of Plastic Surgery. 52 (1): 100–108. doi:10.1055/s-0039-1688105. PMC 6664842. PMID 31456618.
118. Chiodo C, Bluman EM (2011-10-21). Tendon transfers in the foot and ankle. Saunders. p. 421. ISBN 978-1-4557-0924-3. Retrieved 1 January 2020.
119. Lunt P, Upadhyaya M, Koch MC (2004). "Genotype-phenotype relationships in FSHD". In Upadhyaya M, Cooper DN (eds.). FSHD Facioscapulohumeral Muscular Dystrophy: Clinical Medidne and Molecular Cell Biology. BIOS Scientific Publishers Limited. p. 157.
120. Vincenten SC, Mul K, Schreuder TH, Voermans NC, Horlings CG, van Engelen BG (July 2021). "nnExploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy". Neuromuscular Disorders. 31 (9): 824–828. doi:10.1016/j.nmd.2021.07.005. hdl:2066/239258. ISSN 0960-8966. PMID 34407911.
121. ^ Massey JM, Gable KL (1 February 2022). "Neuromuscular Disorders and Pregnancy". Continuum (Minneapolis, Minn.). 28 (1): 55–71. doi:10.1212/CON.0000000000001069. PMID 35133311. S2CID 246651681.
122. ^ Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E, Weinreich SS, Verbeek AL, van Engelen BG (2014). "Population-based incidence and prevalence of facioscapulohumeral dystrophy". Neurology. 83 (12): 1056–9. doi:10.1212/WNL.0000000000000797. PMC 4166358. PMID 25122204.
123. Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG (2015). "The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature". Journal of Neuromuscular Diseases. 2 (1): 73–85. doi:10.3233/JND-140045. PMID 28198707.
124. Teveroni E, Pellegrino M, Sacconi S, Calandra P, Cascino I, Farioli-Vecchioli S, Puma A, Garibaldi M, Morosetti R, Tasca G, Ricci E, Trevisan CP, Galluzzi G, Pontecorvi A, Crescenzi M, Deidda G, Moretti F (3 April 2017). "Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity". The Journal of Clinical Investigation. 127 (4): 1531–1545. doi:10.1172/JCI89401. PMC 5373881. PMID 28263188.
125. Mul K, Horlings C, Voermans NC, Schreuder T, van Engelen B (June 2018). "Lifetime endogenous estrogen exposure and disease severity in female patients with facioscapulohumeral muscular dystrophy". Neuromuscular Disorders. 28 (6): 508–511. doi:10.1016/j.nmd.2018.02.012. hdl:2066/194350. PMID 29655530.
126. Duchenne GB (1868). "De la paralysie musculaire pseudo-hypertrophique, ou paralysie myo-sclérosique". Arch. Gen. Med. (in French). 11. Bibliothèque nationale de France: 5–25, 179–209, 305–321, 421–443, 552–588. Retrieved 18 May 2020.
127. ^ Landouzy-Dejerine syndrome, whonamedit.com, date accessed March 11, 2007
128. Landouzy, Dejerine (1884). "De la myopathie atrophique progressive (myopathie héréditaire, débutant dans l'enfance par la face, sans altération du système nerveux)". Comptes Rendus de l'Académie des Sciences. 98: 53–55.
129. Landouzy, Dejerine (1886). "Contribution à l'étude de la myopathie atrophique progressive (myopathie atrophique progressive, à type scapulo-huméral)". Comptes Rendus des Séances de la Société de Biologie. 38: 478–481.
130. Tyler F, Stephens FE (April 1950). "Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family". Annals of Internal Medicine. 32 (4): 640–660. doi:10.7326/0003-4819-32-4-640. PMID 15411118.
131. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (Jul 31, 1987). "Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals". Cell. 50 (3): 509–517. doi:10.1016/0092-8674(87)90504-6. PMID 3607877. S2CID 35668717.
132. Wijmenga C, Padberg GW, Moerer P, et al. (April 1991). "Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization". Genomics. 9 (4): 570–575. doi:10.1016/0888-7543(91)90348-I. PMID 2037288.
133. Gilbert JR, Stajich JM, Wall S, et al. (Aug 1993). "Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD)". American Journal of Human Genetics. 53 (2): 401–408. PMC 1682358. PMID 8328457.
134. ^ Winokur ST, Bengtsson U, Feddersen J, et al. (May 1994). "The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease". Chromosome Research. 2 (3): 225–234. doi:10.1007/bf01553323. PMID 8069466. S2CID 6933736.
135. Hewitt JE, Lyle R, Clark LN, et al. (Aug 1994). "Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy". Human Molecular Genetics. 3 (8): 1287–1295. doi:10.1093/hmg/3.8.1287. PMID 7987304.
136. Gilbert JR, Speer MC, Stajich J, et al. (Oct 1995). "Exclusion mapping of chromosomal regions which cross hybridise to FSHD1A associated markers in FSHD1B". Journal of Medical Genetics. 32 (10): 770–773. doi:10.1136/jmg.32.10.770. PMC 1051697. PMID 8558552.
137. van Deutekom JC, Lemmers RJ, Grewal PK, et al. (May 1996). "Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35". Human Molecular Genetics. 5 (5): 581–590. doi:10.1093/hmg/5.5.581. PMID 8733123.
138. ^ Kowaljow V, Marcowycz A, Ansseau E, et al. (Aug 2007). "The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein". Neuromuscular Disorders. 17 (8): 611–623. doi:10.1016/j.nmd.2007.04.002. PMID 17588759. S2CID 25926418.
139. Gabriels J, Beckers MC, Ding H, et al. (Aug 5, 1999). "Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element". Gene. 236 (1): 25–32. doi:10.1016/S0378-1119(99)00267-X. PMID 10433963.
140. Tsien F, Sun B, Hopkins NE, et al. (Nov 2001). "Methylation of the FSHD syndrome-linked subtelomeric repeat in normal and FSHD cell cultures and tissues". Molecular Genetics and Metabolism. 74 (3): 322–331. doi:10.1006/mgme.2001.3219. PMID 11708861.
141. Lemmers RJ, de Kievit P, Sandkuijl L, et al. (Oct 2002). "Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere". Nature Genetics. 32 (2): 235–236. doi:10.1038/ng999. PMID 12355084. S2CID 28107557.
142. Gabellini D, Green MR, Tupler R (Aug 9, 2002). "Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle". Cell. 110 (3): 339–348. doi:10.1016/S0092-8674(02)00826-7. hdl:11380/459475. PMID 12176321. S2CID 16396883.
143. van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. (Dec 2003). "Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy". Nature Genetics. 35 (4): 315–317. doi:10.1038/ng1262. PMID 14634647. S2CID 28696708.
144. Lemmers RJ, Wohlgemuth M, Frants RR, Padberg GW, Morava E, van der Maarel SM (Dec 2004). "Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy". The American Journal of Human Genetics. 75 (6): 1124–1130. doi:10.1086/426035. PMC 1182148. PMID 15467981.
145. Gabellini D, D'Antona G, Moggio M, et al. (Feb 23, 2006). "Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1". Nature. 439 (7079): 973–977. Bibcode:2006Natur.439..973G. doi:10.1038/nature04422. PMID 16341202. S2CID 4427465.
146. Clapp J, Mitchell LM, Bolland DJ, et al. (Aug 2007). "Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy". The American Journal of Human Genetics. 81 (2): 264–279. doi:10.1086/519311. PMC 1950813. PMID 17668377.
147. Dixit M, Ansseau E, Tassin A, et al. (Nov 13, 2007). "DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1". Proceedings of the National Academy of Sciences of the USA. 104 (46): 18157–18162. Bibcode:2007PNAS..10418157D. doi:10.1073/pnas.0708659104. PMC 2084313. PMID 17984056.
148. de Greef JC, Lemmers RJ, van Engelen BG, et al. (Oct 2009). "Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD". Human Mutation. 30 (10): 1449–1459. CiteSeerX 10.1.1.325.8388. doi:10.1002/humu.21091. PMID 19728363. S2CID 14517505.
149. Snider L, Asawachaicharn A, Tyler AE, et al. (Jul 1, 2009). "RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy". Human Molecular Genetics. 18 (13): 2414–2430. doi:10.1093/hmg/ddp180. PMC 2694690. PMID 19359275.
150. ^ Kolata G (19 August 2010). "Reanimated 'Junk' DNA Is Found to Cause Disease". The New York Times. Retrieved 29 August 2010.
151. ^ "Research Milestones Achieved by FSH Society Research". FSH Society. Archived from the original on 2010-08-23. Retrieved 2024-02-21.
152. Scionti I, Greco F, Ricci G, et al. (Apr 6, 2012). "Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy". The American Journal of Human Genetics. 90 (4): 628–635. doi:10.1016/j.ajhg.2012.02.019. PMC 3322229. PMID 22482803.
153. Geng LN, Yao Z, Snider L, et al. (Jan 17, 2012). "DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy". Developmental Cell. 22 (1): 38–51. doi:10.1016/j.devcel.2011.11.013. PMC 3264808. PMID 22209328.
154. Jones TI, Chen JC, Rahimov F, et al. (Oct 15, 2012). "Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis". Human Molecular Genetics. 21 (20): 4419–4430. doi:10.1093/hmg/dds284. PMC 3459465. PMID 22798623.
155. Krom YD, Thijssen PE, Young JM, et al. (Apr 2013). "Intrinsic Epigenetic Regulation of the D4Z4 Macrosatellite Repeat in a Transgenic Mouse Model for FSHD". PLOS Genetics. 9 (4): e1003415. doi:10.1371/journal.pgen.1003415. PMC 3616921. PMID 23593020.
156. Ferreboeuf M, Mariot V, Bessieres B, et al. (Jan 1, 2014). "DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles". Human Molecular Genetics. 23 (1): 171–181. doi:10.1093/hmg/ddt409. PMID 23966205.
157. Tawil R, McDermott MP, Pandya S, King W, Kissel J, Mendell JR, Griggs RC (January 1997). "A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group". Neurology. 48 (1): 46–9. doi:10.1212/wnl.48.1.46. PMID 9008492. S2CID 729275.
158. Kissel JT, McDermott MP, Natarajan R, Mendell JR, Pandya S, King WM, Griggs RC, Tawil R (May 1998). "Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group". Neurology. 50 (5): 1402–6. doi:10.1212/wnl.50.5.1402. PMID 9595995. S2CID 24848310.
159. Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, Tawil R, FSH-DY G (23 October 2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy". Neurology. 57 (8): 1434–40. doi:10.1212/wnl.57.8.1434. PMID 11673585. S2CID 28093111.
160. van der Kooi EL, Vogels OJ, van Asseldonk RJ, Lindeman E, Hendriks JC, Wohlgemuth M, van der Maarel SM, Padberg GW (24 August 2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy". Neurology. 63 (4): 702–8. doi:10.1212/01.wnl.0000134660.30793.1f. PMID 15326246. S2CID 22778327.
161. ^ Campbell AE, Oliva J, Yates MP, Zhong JW, Shadle SC, Snider L, Singh N, Tai S, Hiramuki Y, Tawil R, van der Maarel SM, Tapscott SJ, Sverdrup FM (4 September 2017). "BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells". Skeletal Muscle. 7 (1): 16. doi:10.1186/s13395-017-0134-x. PMC 5584331. PMID 28870238.
162. Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, Kissel JT (24 April 2007). "Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy". Neurology. 68 (17): 1428–9. doi:10.1212/01.wnl.0000264017.08217.39. PMID 17452589. S2CID 361422.
163. Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029
164. Malcolm E (18 June 2019). "ACE-083". Muscular Dystrophy News. Retrieved 19 December 2019.
165. Vultaggio M (5 October 2018). "Why Rufus Sewell wanted to play 'Man in the High Castle' villain John Smith". Newsweek. Archived from the original on 6 November 2018. Retrieved 12 April 2022.
166. Kakutani M (9 June 2006). "'Stuart: A Life Backwards,' by Alexander Masters, a Portrait of a Homeless Man". The New York Times. Archived from the original on 16 January 2018.
167. White A (2023-12-19). "'Ramy' Star Steve Way Boards Indie Drama 'Good Bad Things' as Executive Producer (Exclusive)". The Hollywood Reporter. Retrieved 2024-01-31.
168. jkinoshita (2022-08-25). "New movie will feature man with FSHD". FSHD Society. Retrieved 2024-01-31.
169. "A disability advocate preserves his voice with iPhone". Apple Newsroom. Retrieved 2024-02-21.
170. ^ Kinoshita J (16 August 2019). "What's in a name? – FSHD Society". FSHD Society. Archived from the original on 12 April 2022. Retrieved 18 August 2019.
171. ^ "Our History". FSHD Society. Archived from the original on 27 February 2022.
172. ^ Bartlett J (19 August 2014). "Dan Perez: Living with and fighting against a deadly disease". Boston Business Journal. Archived from the original on 12 April 2022. Retrieved 12 April 2022.
173. "FSHD Society". NORD (National Organization for Rare Disorders). Archived from the original on 2022-05-13. Retrieved 2022-04-12.
174. "FSHD Society Achieves Accreditation from BBB Wise Giving Alliance". Prweb. 26 April 2022. Archived from the original on 29 April 2022. Retrieved 29 April 2022.
175. "This Is FSHD". HuffPost. 16 July 2014. Archived from the original on 2 August 2019. Retrieved 12 April 2022.
176. Krummey C (30 March 2017). "Kirkland couple raises $3.2 million for FSH muscular dystrophy research". Kirkland Reporter. Archived from the original on 16 June 2017. Retrieved 9 April 2022.
177. "About Us: Friends of FSH Research". Friends of FSH Research. Archived from the original on 17 February 2020. Retrieved 9 April 2022.
178. AMRA Medical (13 Oct 2021). "AMRA Medical's Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development". Cision PR Newswire. Archived from the original on 1 November 2021. Retrieved 9 April 2022.
179. Avidity Biosciences, Inc. (16 August 2021). "Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use". Cision PR Newswire. Archived from the original on 16 August 2021.
180. Overington C (24 September 2016). "He's physically wasting but his brain is sharp. Former Macquarie banker Bill Moss is back in business". The Australian.
181. ^ Chancellor J (7 September 2020). "Buyer swoops on Brett Whiteley's corella". The Australian. Retrieved 9 April 2022.
182. ^ Tasker SJ (26 May 2018). "Bill Moss, the single-minded biotech and a search for a cure". The Australian. Retrieved 9 April 2022.
183. ^ Voermans NC, Vriens-Munoz Bravo M, Padberg GW, Laforêt P, FSHD European Trial Network workshop study g (September 2021). "1st FSHD European Trial Network workshop:Working towards trial readiness across Europe". Neuromuscular Disorders. 31 (9): 907–918. doi:10.1016/j.nmd.2021.07.013. hdl:1887/3505452. PMID 34404575. S2CID 236217036. Archived from the original on Mar 19, 2024.
184. Judd A (8 March 2022). "Lululemon founder Chip Wilson donates $100M to find cure for his illness, 30 years after diagnosis". Global News. Retrieved 9 April 2022.
185. Isola F (23 April 2019). "'You're not going to quit': One step at a time, Nets radio voice Chris Carrino continues to walk tall". The Athletic. Archived from the original on 14 February 2023. Retrieved 9 April 2022.
186. "Actress Breaking Barriers as Broadway's First Lead Actor in Wheelchair". NBC News. March 19, 2024. Retrieved 2024-02-21.
187. "Community Profiles: Actress Madison Ferris". FSHD Straight Talk with Tim Hollenback. Audioboom. Sep 13, 2022. Archived from the original on 2024-02-21. Retrieved 2024-02-21.
188. Shedloski D (24 February 2020). "There's no stopping Morgan Hoffmann in his fight against muscular dystrophy". Golf Digest. Archived from the original on 5 March 2022. Retrieved 12 April 2022.
189. Sandomir R (2018-02-03). "Dr. Arnold Gold, 92, Dies; Made Compassionate Care a Cause". The New York Times. ISSN 0362-4331. Retrieved 2024-02-21.
190. Rickard A, Petek L, Miller D (August 5, 2015). "Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways". Hum. Mol. Genet. 24 (20): 5901–14. doi:10.1093/hmg/ddv315. PMC 4581613. PMID 26246499.
191. "Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy". BioSpace. Retrieved 12 August 2019.
192. "ReDUX4 trial result exceeds expectations". FSHD Society. Wayback Machine. 2021-06-24. Archived from the original on 26 June 2021. Retrieved 26 June 2021.
193. "Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)". ClinicalTrials.gov. United States National Library of Medicine. Retrieved 12 August 2019.
194. "Facio to present at the World Muscle Society Congress". Facio Therapies. 30 September 2019. Retrieved 9 November 2019.
195. "Facio reveals novel mechanism targeting the cause of FSHD". Facio Therapies. 24 June 2019. Retrieved 9 November 2019.
196. Lim KR, Maruyama R, Echigoya Y, Nguyen Q, Zhang A, Khawaja H, Sen Chandra S, Jones T, Jones P, Chen YW, Yokota T (2020-07-14). "Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy". Proceedings of the National Academy of Sciences. 117 (28): 16509–16515. Bibcode:2020PNAS..11716509L. doi:10.1073/pnas.1909649117. ISSN 0027-8424. PMC 7368245. PMID 32601200.
197. Lim KR, Bittel A, Maruyama R, Echigoya Y, Nguyen Q, Huang Y, Dzierlega K, Zhang A, Chen YW, Yokota T (2021-02-03). "DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy". Molecular Therapy: The Journal of the American Society of Gene Therapy. 29 (2): 848–858. doi:10.1016/j.ymthe.2020.10.010. ISSN 1525-0024. PMC 7854280. PMID 33068777.
198. "Arrowhead Pharmaceuticals announces FSHD drug candidate". FSHD Society. 15 April 2021. Retrieved 15 April 2021.
199. "Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform". Businesswire. 15 April 2021. Retrieved 15 April 2021.
200. Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ (December 2021). "Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy". Nature Communications. 12 (1): 7128. Bibcode:2021NatCo..12.7128S. doi:10.1038/s41467-021-27430-1. PMC 8654987. PMID 34880230.
201. Joubert R, Mariot V, Charpentier M, Concordet JP, Dumonceaux J (23 December 2020). "Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?". Journal of Personalized Medicine. 11 (1): 7. doi:10.3390/jpm11010007. PMC 7822190. PMID 33374516.
202. DeSimone AM, Leszyk J, Wagner K, Emerson CP (11 December 2019). "Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy". Science Advances. 5 (12): eaaw7099. Bibcode:2019SciA....5.7099D. doi:10.1126/sciadv.aaw7099. PMC 6905861. PMID 31844661.
203. Bosnakovski D, da Silva MT, Sunny ST, Ener ET, Toso EA, Yuan C, Cui Z, Walters MA, Jadhav A, Kyba M (September 2019). "A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death". Science Advances. 5 (9): eaaw7781. Bibcode:2019SciA....5.7781B. doi:10.1126/sciadv.aaw7781. PMC 6739093. PMID 31535023.
204. Passerieux E, Hayot M, Jaussent A, Carnac G, Gouzi F, Pillard F, Picot MC, Böcker K, Hugon G, Pincemail J, Defraigne JO, Verrips T, Mercier J, Laoudj-Chenivesse D (April 2015). "Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial" (PDF). Free Radical Biology & Medicine. 81: 158–69. doi:10.1016/j.freeradbiomed.2014.09.014. PMID 25246239. S2CID 10971952.
205. Han JJ, Kurillo G, Abresch RT, de Bie E, Nicorici A, Bajcsy R (February 2015). "Reachable Workspace in Facioscapulohumeral muscular dystrophy (FSHD) by Kinect". Muscle & Nerve. 51 (2): 168–175. doi:10.1002/mus.24287. ISSN 0148-639X. PMC 4233016. PMID 24828906.
206. Dany A, Barbe C, Rapin A, Réveillère C, Hardouin JB, Morrone I, Wolak-Thierry A, Dramé M, Calmus A, Sacconi S, Bassez G, Tiffreau V, Richard I, Gallais B, Prigent H, Taiar R, Jolly D, Novella JL, Boyer FC (2015). "Construction of a Quality of Life Questionnaire for slowly progressive neuromuscular disease". Quality of Life Research. 24 (11): 2615–2623. doi:10.1007/s11136-015-1013-8. ISSN 0962-9343. PMID 26141500. S2CID 25834947.
207. Mul K, Hamadeh T, Horlings C, Tawil R, Statland JM, Sacconi S, Corbett AJ, Voermans NC, Faber CG, van Engelen B, Merkies I (10 April 2021). "The FacioScapuloHumeral muscular Dystrophy Rasch-built Overall Disability Scale (FSHD-RODS)". European Journal of Neurology. 28 (7): 2339–2348. doi:10.1111/ene.14863. PMC 8251612. PMID 33838063.
208. Eichinger K, Heatwole C, Iyadurai S, King W, Baker L, Heininger S, Bartlett A, Dilek N, Martens WB, Mcdermott M, Kissel JT, Tawil R, Statland JM (2018-01-30). "Facioscapulohumeral muscular dystrophy functional composite outcome measure". Muscle & Nerve. 58: 72–78. doi:10.1002/mus.26088. PMC 6066464. PMID 29381807.

External links

• World FSHD Alliance: FSHD patient advocacy organizations across the world
• list of clinical trials for FSHD, Clinicaltrials.gov.
• fsh at NIH/UW GeneTests

• Muscular dystrophy
• Rare diseases